메뉴 건너뛰기




Volumn 27, Issue 2, 2013, Pages 113-148

Immunotherapy of multiple sclerosis: The state of the art

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DACLIZUMAB; FINGOLIMOD; FUMADERM; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM PENTETATE; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; LAQUINIMOD; LIPOCORTIN 1; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; RECOMBINANT INTERFERON; RITUXIMAB; ROQUINIMEX; TACROLIMUS; TERIFLUNOMIDE; UNINDEXED DRUG;

EID: 84877064892     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0011-z     Document Type: Review
Times cited : (23)

References (304)
  • 1
    • 54149084585 scopus 로고    scopus 로고
    • Multiple sclerosis
    • 1:CAS:528:DC%2BD1cXht12gtLvN 18970977 10.1016/S0140-6736(08)61620-7
    • Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17.
    • (2008) Lancet , vol.372 , Issue.9648 , pp. 1502-1517
    • Compston, A.1    Coles, A.2
  • 2
    • 33644607018 scopus 로고    scopus 로고
    • Multiple sclerosis: The plaque and its pathogenesis
    • 1:CAS:528:DC%2BD28XitVertLc%3D 16510748 10.1056/NEJMra052130
    • Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-55.
    • (2006) N Engl J Med , vol.354 , Issue.9 , pp. 942-955
    • Frohman, E.M.1    Racke, M.K.2    Raine, C.S.3
  • 3
    • 0035554898 scopus 로고    scopus 로고
    • Multiple sclerosis: A two-stage disease
    • 1:CAS:528:DC%2BD3MXmsFeju7o%3D 11526378 10.1038/ni0901-762
    • Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2(9):762-4.
    • (2001) Nat Immunol , vol.2 , Issue.9 , pp. 762-764
    • Steinman, L.1
  • 4
    • 0032576752 scopus 로고    scopus 로고
    • Axonal transection in the lesions of multiple sclerosis
    • 1:STN:280:DyaK1c%2Fpt1SksA%3D%3D 9445407 10.1056/NEJM199801293380502
    • Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-85.
    • (1998) N Engl J Med , vol.338 , Issue.5 , pp. 278-285
    • Trapp, B.D.1    Peterson, J.2    Ransohoff, R.M.3    Rudick, R.4    Mork, S.5    Bo, L.6
  • 5
    • 0027957780 scopus 로고
    • Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis
    • 1:CAS:528:DyaK2cXhs1Wms7w%3D 7509366 10.1084/jem.179.3.973
    • Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994;179(3):973-84.
    • (1994) J Exp Med , vol.179 , Issue.3 , pp. 973-984
    • Zhang, J.1    Markovic-Plese, S.2    Lacet, B.3    Raus, J.4    Weiner, H.L.5    Hafler, D.A.6
  • 6
    • 0025138302 scopus 로고
    • T cells responsive to myelin basic protein in patients with multiple sclerosis
    • 1:STN:280:DyaK3c7ktVOgtQ%3D%3D 1689076 10.1126/science.1689076
    • Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 1990;247(4943):718-21.
    • (1990) Science , vol.247 , Issue.4943 , pp. 718-721
    • Allegretta, M.1    Nicklas, J.A.2    Sriram, S.3    Albertini, R.J.4
  • 7
    • 0029079836 scopus 로고
    • A review of T-cell receptors in multiple sclerosis: Clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide
    • 1:CAS:528:DyaK2MXoslOisrc%3D 7544075 10.1111/j.1749-6632.1995.tb44522.x
    • Wucherpfennig KW, Hafler DA. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann N Y Acad Sci. 1995;756:241-58.
    • (1995) Ann N y Acad Sci , vol.756 , pp. 241-258
    • Wucherpfennig, K.W.1    Hafler, D.A.2
  • 8
    • 77956338425 scopus 로고    scopus 로고
    • Memory CD4 + CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens
    • 1:CAS:528:DC%2BC3cXhtFGjtrjK 20554330 10.1016/j.jneuroim.2010.05.025
    • Venken K, Hellings N, Hensen K, Rummens JL, Stinissen P. Memory CD4 + CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens. J Neuroimmunol. 2010;226(1-2):185-91.
    • (2010) J Neuroimmunol , vol.226 , Issue.1-2 , pp. 185-191
    • Venken, K.1    Hellings, N.2    Hensen, K.3    Rummens, J.L.4    Stinissen, P.5
  • 9
    • 47249128991 scopus 로고    scopus 로고
    • Th17 cells in human disease
    • 1:CAS:528:DC%2BD1cXptlGls7s%3D 18613831 10.1111/j.1600-065X.2008.00628.x
    • Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113.
    • (2008) Immunol Rev , vol.223 , pp. 87-113
    • Tesmer, L.A.1    Lundy, S.K.2    Sarkar, S.3    Fox, D.A.4
  • 10
    • 61949463911 scopus 로고    scopus 로고
    • IL-17 and Th17 Cells
    • 1:CAS:528:DC%2BD1MXlsFSltrY%3D 19132915 10.1146/annurev.immunol.021908. 132710
    • Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
    • (2009) Annu Rev Immunol , vol.27 , pp. 485-517
    • Korn, T.1    Bettelli, E.2    Oukka, M.3    Kuchroo, V.K.4
  • 11
    • 34948909646 scopus 로고    scopus 로고
    • Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
    • 1:CAS:528:DC%2BD2sXhtFagsbzK 17828272 10.1038/nm1651
    • Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173-5.
    • (2007) Nat Med , vol.13 , Issue.10 , pp. 1173-1175
    • Kebir, H.1    Kreymborg, K.2    Ifergan, I.3    Dodelet-Devillers, A.4    Cayrol, R.5    Bernard, M.6
  • 12
    • 0342906187 scopus 로고    scopus 로고
    • Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
    • 1:STN:280:DC%2BD3czgvFektA%3D%3D 10852536 10.1002/1531-8249(200006)47: 6<707: AID-ANA3>3.0.CO;2-Q
    • Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707-17.
    • (2000) Ann Neurol , vol.47 , Issue.6 , pp. 707-717
    • Lucchinetti, C.1    Bruck, W.2    Parisi, J.3    Scheithauer, B.4    Rodriguez, M.5    Lassmann, H.6
  • 13
    • 0027409052 scopus 로고
    • Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: Correlation with TNF-alpha and blood-brain barrier damage
    • 1:CAS:528:DyaK3sXkvFaqs74%3D 8096220 10.1016/0165-5728(93)90070-F
    • Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol. 1993;43(1-2):15-21.
    • (1993) J Neuroimmunol , vol.43 , Issue.1-2 , pp. 15-21
    • Sharief, M.K.1    Noori, M.A.2    Ciardi, M.3    Cirelli, A.4    Thompson, E.J.5
  • 14
    • 0027497847 scopus 로고
    • Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis
    • 1:STN:280:DyaK3s7ntF2mtQ%3D%3D 8437006 10.1136/jnnp.56.2.169
    • Sharief MK, Thompson EJ. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993;56(2):169-74.
    • (1993) J Neurol Neurosurg Psychiatry , vol.56 , Issue.2 , pp. 169-174
    • Sharief, M.K.1    Thompson, E.J.2
  • 15
    • 0027751693 scopus 로고
    • Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis
    • 1:STN:280:DyaK2c%2Fnslequg%3D%3D 8255476 10.1212/WNL.43.12.2679
    • Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology. 1993;43(12):2679-82.
    • (1993) Neurology , vol.43 , Issue.12 , pp. 2679-2682
    • Tsukada, N.1    Matsuda, M.2    Miyagi, K.3    Yanagisawa, N.4
  • 16
    • 0027311194 scopus 로고
    • Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy
    • 1:STN:280:DyaK3s3ntVCksA%3D%3D 8098933 10.1002/ana.410330614
    • Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. Ann Neurol. 1993;33(6):646-9.
    • (1993) Ann Neurol , vol.33 , Issue.6 , pp. 646-649
    • Tsukada, N.1    Miyagi, K.2    Matsuda, M.3    Yanagisawa, N.4
  • 17
    • 0027233996 scopus 로고
    • Adhesion of cerebral endothelial cells to lymphocytes from patients with multiple sclerosis
    • 1:STN:280:DyaK3szltVWjtw%3D%3D 8347775 10.3109/08916939309079236
    • Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Adhesion of cerebral endothelial cells to lymphocytes from patients with multiple sclerosis. Autoimmunity. 1993;14(4):329-33.
    • (1993) Autoimmunity , vol.14 , Issue.4 , pp. 329-333
    • Tsukada, N.1    Matsuda, M.2    Miyagi, K.3    Yanagisawa, N.4
  • 18
    • 0028053052 scopus 로고
    • Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis
    • 1:STN:280:DyaK2c7htlGquw%3D%3D 7506877 10.1002/ana.410350114
    • Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol. 1994;35(1):89-97.
    • (1994) Ann Neurol , vol.35 , Issue.1 , pp. 89-97
    • Washington, R.1    Burton, J.2    Todd III, R.F.3    Newman, W.4    Dragovic, L.5    Dore-Duffy, P.6
  • 19
    • 0026506799 scopus 로고
    • Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin
    • 1:CAS:528:DyaK38Xhslaisbw%3D 1538783 10.1038/356063a0
    • Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356(6364):63-6.
    • (1992) Nature , vol.356 , Issue.6364 , pp. 63-66
    • Yednock, T.A.1    Cannon, C.2    Fritz, L.C.3    Sanchez-Madrid, F.4    Steinman, L.5    Karin, N.6
  • 20
    • 33644584352 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    • 1:CAS:528:DC%2BD28XitVertL4%3D 16510744 10.1056/NEJMoa044397
    • Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
    • (2006) N Engl J Med , vol.354 , Issue.9 , pp. 899-910
    • Polman, C.H.1    O'Connor, P.W.2    Havrdova, E.3    Hutchinson, M.4    Kappos, L.5    Miller, D.H.6
  • 21
    • 41649114547 scopus 로고    scopus 로고
    • B-cell-targeted treatment for multiple sclerosis: Mechanism of action and clinical data
    • 1:CAS:528:DC%2BD1cXltl2htL4%3D 18388796 10.1097/01.wco.0000313360.38306. ab
    • Hawker K. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol. 2008;21(Suppl. 1):S19-25.
    • (2008) Curr Opin Neurol , vol.21 , Issue.SUPPL. 1
    • Hawker, K.1
  • 22
    • 42649099687 scopus 로고    scopus 로고
    • B lymphocytes: Chief players and therapeutic targets in autoimmune diseases
    • 1:CAS:528:DC%2BD1cXnsVOjtr4%3D 18508550 10.2741/3044
    • Zouali M. B lymphocytes: chief players and therapeutic targets in autoimmune diseases. Front Biosci. 2008;13:4852-61.
    • (2008) Front Biosci , vol.13 , pp. 4852-4861
    • Zouali, M.1
  • 23
    • 21944448962 scopus 로고    scopus 로고
    • Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis
    • 15800022 10.1093/brain/awh486
    • Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005;128(Pt 7):1667-76.
    • (2005) Brain , vol.128 , Issue.PART 7 , pp. 1667-1676
    • Cepok, S.1    Rosche, B.2    Grummel, V.3    Vogel, F.4    Zhou, D.5    Sayn, J.6
  • 24
    • 33646810060 scopus 로고    scopus 로고
    • The B cell response in multiple sclerosis
    • 1:CAS:528:DC%2BD28XlvVOrtb0%3D 16687047 10.1179/016164106X98099
    • Owens GP, Bennett JL, Gilden DH, Burgoon MP. The B cell response in multiple sclerosis. Neurol Res. 2006;28(3):236-44.
    • (2006) Neurol Res , vol.28 , Issue.3 , pp. 236-244
    • Owens, G.P.1    Bennett, J.L.2    Gilden, D.H.3    Burgoon, M.P.4
  • 25
    • 0019469331 scopus 로고
    • Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown
    • 1:STN:280:DyaL38%2Fit1ejsg%3D%3D 7025748 10.1002/ana.410100205
    • Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol. 1981;10(2):149-58.
    • (1981) Ann Neurol , vol.10 , Issue.2 , pp. 149-158
    • Prineas, J.W.1    Graham, J.S.2
  • 26
    • 0034120945 scopus 로고    scopus 로고
    • The role of B cells and autoantibodies in multiple sclerosis
    • 1:CAS:528:DC%2BD3cXksFSmtLw%3D 10852535 10.1002/1531-8249(200006)47: 6<694: AID-ANA2>3.0.CO;2-W
    • Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol. 2000;47(6):694-706.
    • (2000) Ann Neurol , vol.47 , Issue.6 , pp. 694-706
    • Archelos, J.J.1    Storch, M.K.2    Hartung, H.P.3
  • 27
    • 2442708947 scopus 로고    scopus 로고
    • Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis
    • 15193029 10.1111/j.1750-3639.2004.tb00049.x
    • Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164-74.
    • (2004) Brain Pathol , vol.14 , Issue.2 , pp. 164-174
    • Serafini, B.1    Rosicarelli, B.2    Magliozzi, R.3    Stigliano, E.4    Aloisi, F.5
  • 28
    • 30344446249 scopus 로고    scopus 로고
    • Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment
    • 16280350
    • Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129(Pt 1):200-11.
    • (2006) Brain , vol.129 , Issue.PART 1 , pp. 200-211
    • Krumbholz, M.1    Theil, D.2    Cepok, S.3    Hemmer, B.4    Kivisakk, P.5    Ransohoff, R.M.6
  • 29
    • 34249700046 scopus 로고    scopus 로고
    • Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
    • 17438020
    • Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089-104.
    • (2007) Brain , vol.130 , Issue.PART 4 , pp. 1089-1104
    • Magliozzi, R.1    Howell, O.2    Vora, A.3    Serafini, B.4    Nicholas, R.5    Puopolo, M.6
  • 30
    • 36148952124 scopus 로고    scopus 로고
    • Toward the development of rational therapies in multiple sclerosis: What is on the horizon?
    • 1:CAS:528:DC%2BD2sXhsVSjurrI 17969020 10.1002/ana.21289
    • Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol. 2007;62(4):314-26.
    • (2007) Ann Neurol , vol.62 , Issue.4 , pp. 314-326
    • Hemmer, B.1    Hartung, H.P.2
  • 31
    • 0032758846 scopus 로고    scopus 로고
    • A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
    • 1:STN:280:DC%2BD3c%2FlsFCmtQ%3D%3D 10589540 10.1002/1531-8249(199912)46: 6<878: AID-ANA10>3.0.CO;2-Q
    • Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878-86.
    • (1999) Ann Neurol , vol.46 , Issue.6 , pp. 878-886
    • Weinshenker, B.G.1    O'Brien, P.C.2    Petterson, T.M.3    Noseworthy, J.H.4    Lucchinetti, C.F.5    Dodick, D.W.6
  • 32
    • 0030275527 scopus 로고    scopus 로고
    • Immunomodulation with linomide: Possible novel therapy for multiple sclerosis
    • 1:CAS:528:DyaK2sXhvV2itrY%3D 9345375
    • Abramsky O, Lehmann D, Karussis D. Immunomodulation with linomide: possible novel therapy for multiple sclerosis. Mult Scler. 1996;2(4):206-10.
    • (1996) Mult Scler , vol.2 , Issue.4 , pp. 206-210
    • Abramsky, O.1    Lehmann, D.2    Karussis, D.3
  • 33
    • 0029832923 scopus 로고    scopus 로고
    • Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
    • 1:CAS:528:DyaK28Xls1Glsbs%3D 8757002 10.1212/WNL.47.2.341
    • Karussis DM, Meiner Z, Lehmann D, Gomori JM, Schwarz A, Linde A, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology. 1996;47(2):341-6.
    • (1996) Neurology , vol.47 , Issue.2 , pp. 341-346
    • Karussis, D.M.1    Meiner, Z.2    Lehmann, D.3    Gomori, J.M.4    Schwarz, A.5    Linde, A.6
  • 34
    • 0027496152 scopus 로고
    • Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide
    • 1:CAS:528:DyaK2cXitlGlt70%3D 8239559 10.1002/ana.410340506
    • Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol. 1993;34(5):654-60.
    • (1993) Ann Neurol , vol.34 , Issue.5 , pp. 654-660
    • Karussis, D.M.1    Lehmann, D.2    Slavin, S.3    Vourka-Karussis, U.4    Mizrachi-Koll, R.5    Ovadia, H.6
  • 35
    • 0034955141 scopus 로고    scopus 로고
    • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis
    • 1:STN:280:DC%2BD38%2FitFOhug%3D%3D 11456302 10.1002/ana.1032
    • McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-7.
    • (2001) Ann Neurol , vol.50 , Issue.1 , pp. 121-127
    • McDonald, W.I.1    Compston, A.2    Edan, G.3    Goodkin, D.4    Hartung, H.P.5    Lublin, F.D.6
  • 36
    • 0014781373 scopus 로고
    • Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo: Final report
    • 1:STN:280:DyaE3c7msVWksA%3D%3D 4314823 10.1212/WNL.20.5-Part-2.1
    • Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo: final report. Neurology. 1970;20(5):1-59.
    • (1970) Neurology , vol.20 , Issue.5 , pp. 1-59
    • Rose, A.S.1    Kuzma, J.W.2    Kurtzke, J.F.3    Namerow, N.S.4    Sibley, W.A.5    Tourtellotte, W.W.6
  • 37
    • 0020536935 scopus 로고
    • Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections
    • 1:STN:280:DyaL3s7nsFOjsw%3D%3D 6220603 10.1016/0002-9343(83)91029-X
    • Abbruzzese JL, Rocco LE, Laskin OL, Skubitz KM, McGaughey MD, Lipsky JJ. Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections. Am J Med. 1983;74(4):694-9.
    • (1983) Am J Med , vol.74 , Issue.4 , pp. 694-699
    • Abbruzzese, J.L.1    Rocco, L.E.2    Laskin, O.L.3    Skubitz, K.M.4    McGaughey, M.D.5    Lipsky, J.J.6
  • 38
    • 0025913743 scopus 로고
    • Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis
    • 1:STN:280:DyaK3Mzis1ansQ%3D%3D 1866009 10.1212/WNL.41.8.1219
    • Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991;41(8):1219-22.
    • (1991) Neurology , vol.41 , Issue.8 , pp. 1219-1222
    • Barkhof, F.1    Hommes, O.R.2    Scheltens, P.3    Valk, J.4
  • 39
    • 0026586019 scopus 로고
    • A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group
    • 1:STN:280:DyaK387jtFSktg%3D%3D 1734247 10.1056/NEJM199202273260901
    • Beck RW, Cleary PA, Anderson MM Jr. Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581-8.
    • (1992) N Engl J Med. , vol.326 , Issue.9 , pp. 581-588
    • Beck, R.W.1    Cleary, P.A.2    Anderson Jr., M.M.3    Keltner, J.L.4    Shults, W.T.5    Kaufman, D.I.6
  • 40
    • 0025741072 scopus 로고
    • Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines
    • 1:STN:280:DyaK38%2FksVGksw%3D%3D 1940938 10.1136/jnnp.54.8.683
    • Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 1991;54(8):683-8.
    • (1991) J Neurol Neurosurg Psychiatry , vol.54 , Issue.8 , pp. 683-688
    • Miller, D.H.1    Barkhof, F.2    Berry, I.3    Kappos, L.4    Scotti, G.5    Thompson, A.J.6
  • 41
    • 0026755758 scopus 로고
    • High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect
    • 1:STN:280:DyaK38zhsl2huw%3D%3D 1619410 10.1136/jnnp.55.6.450
    • Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry. 1992;55(6):450-3.
    • (1992) J Neurol Neurosurg Psychiatry , vol.55 , Issue.6 , pp. 450-453
    • Miller, D.H.1    Thompson, A.J.2    Morrissey, S.P.3    Macmanus, D.G.4    Moore, S.G.5    Kendall, B.E.6
  • 42
    • 0024571676 scopus 로고
    • Quantitative magnetic resonance imaging in multiple sclerosis: The effect of high dose intravenous methylprednisolone
    • 1:STN:280:DyaL1M3hsFyltw%3D%3D 2709033 10.1136/jnnp.52.1.14
    • Kesselring J, Miller DH, MacManus DG, Johnson G, Milligan NM, Scolding N, et al. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry. 1989;52(1):14-7.
    • (1989) J Neurol Neurosurg Psychiatry , vol.52 , Issue.1 , pp. 14-17
    • Kesselring, J.1    Miller, D.H.2    Macmanus, D.G.3    Johnson, G.4    Milligan, N.M.5    Scolding, N.6
  • 44
    • 0024361063 scopus 로고
    • Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS
    • 1:STN:280:DyaL1M3psF2msw%3D%3D 2544829 10.1212/WNL.39.7.969
    • Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989;39(7):969-71.
    • (1989) Neurology , vol.39 , Issue.7 , pp. 969-971
    • Thompson, A.J.1    Kennard, C.2    Swash, M.3    Summers, B.4    Yuill, G.M.5    Shepherd, D.I.6
  • 45
    • 0027515341 scopus 로고
    • The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group
    • 1:STN:280:DyaK2c%2FltVSmuw%3D%3D 8232485 10.1056/NEJM199312093292403
    • Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329(24):1764-9.
    • (1993) N Engl J Med , vol.329 , Issue.24 , pp. 1764-1769
    • Beck, R.W.1    Cleary, P.A.2    Trobe, J.D.3    Kaufman, D.I.4    Kupersmith, M.J.5    Paty, D.W.6
  • 47
    • 0023194967 scopus 로고
    • A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects
    • 1:STN:280:DyaL2s3isV2quw%3D%3D 3295122 10.1136/jnnp.50.5.511
    • Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987;50(5):511-6.
    • (1987) J Neurol Neurosurg Psychiatry , vol.50 , Issue.5 , pp. 511-516
    • Milligan, N.M.1    Newcombe, R.2    Compston, D.A.3
  • 48
    • 0029077076 scopus 로고
    • Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis
    • 1:CAS:528:DyaK28XmsVaisbk%3D 7671978 10.1159/000117127
    • Cazzato G, Mesiano T, Antonello R, Monti F, Carraro N, Torre P, et al. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol. 1995;35(4):193-8.
    • (1995) Eur Neurol , vol.35 , Issue.4 , pp. 193-198
    • Cazzato, G.1    Mesiano, T.2    Antonello, R.3    Monti, F.4    Carraro, N.5    Torre, P.6
  • 49
    • 0035833931 scopus 로고    scopus 로고
    • Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
    • 1:CAS:528:DC%2BD3MXotVeisr8%3D 11591843 10.1212/WNL.57.7.1239
    • Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology. 2001;57(7):1239-47.
    • (2001) Neurology , vol.57 , Issue.7 , pp. 1239-1247
    • Zivadinov, R.1    Rudick, R.A.2    De Masi, R.3    Nasuelli, D.4    Ukmar, M.5    Pozzi-Mucelli, R.S.6
  • 50
    • 0027366991 scopus 로고
    • Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose
    • 1:STN:280:DyaK2c%2FksFOiuw%3D%3D 8229035 10.1136/jnnp.56.11.1219
    • Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993;56(11):1219-20.
    • (1993) J Neurol Neurosurg Psychiatry , vol.56 , Issue.11 , pp. 1219-1220
    • Alam, S.M.1    Kyriakides, T.2    Lawden, M.3    Newman, P.K.4
  • 51
    • 0344352481 scopus 로고    scopus 로고
    • Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS
    • 1:CAS:528:DyaK1cXls1ahtbc%3D 9710030 10.1212/WNL.51.2.529
    • Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 1998;51(2):529-34.
    • (1998) Neurology , vol.51 , Issue.2 , pp. 529-534
    • Sellebjerg, F.1    Frederiksen, J.L.2    Nielsen, P.M.3    Olesen, J.4
  • 52
    • 73349112230 scopus 로고    scopus 로고
    • Martinelli Boneschi F, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS
    • 1:CAS:528:DC%2BD1MXhsV2jtbnJ 19949030 10.1212/WNL.0b013e3181c3fd5b
    • Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M. Martinelli Boneschi F, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology. 2009;73(22):1842-8.
    • (2009) Neurology , vol.73 , Issue.22 , pp. 1842-1848
    • Martinelli, V.1    Rocca, M.A.2    Annovazzi, P.3    Pulizzi, A.4    Rodegher, M.5
  • 53
    • 0033592442 scopus 로고    scopus 로고
    • Therapeutic plasma exchange: An update from the Canadian Apheresis Group
    • 1:STN:280:DyaK1MvhtVahtA%3D%3D 10498563
    • Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 1999;131(6):453-62.
    • (1999) Ann Intern Med , vol.131 , Issue.6 , pp. 453-462
    • Clark, W.F.1    Rock, G.A.2    Buskard, N.3    Shumak, K.H.4    Leblond, P.5    Anderson, D.6
  • 54
    • 33747157912 scopus 로고    scopus 로고
    • Plasma exchange in neuroimmunological disorders: Part 2. Treatment of neuromuscular disorders
    • 16908731 10.1001/archneur.63.8.1066
    • Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006;63(8):1066-71.
    • (2006) Arch Neurol , vol.63 , Issue.8 , pp. 1066-1071
    • Lehmann, H.C.1    Hartung, H.P.2    Hetzel, G.R.3    Stuve, O.4    Kieseier, B.C.5
  • 55
    • 70349439268 scopus 로고    scopus 로고
    • Plasmapheresis for neurological disorders
    • 19769448 10.1586/ern.09.81
    • Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother. 2009;9(9):1331-9.
    • (2009) Expert Rev Neurother , vol.9 , Issue.9 , pp. 1331-1339
    • Schroder, A.1    Linker, R.A.2    Gold, R.3
  • 56
    • 0021922953 scopus 로고
    • A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis
    • 1:STN:280:DyaL2M7ltFCjtA%3D%3D 3884114
    • Gordon PA, Carroll DJ, Etches WS, Jeffrey V, Marsh L, Morrice BL, et al. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci. 1985;12(1):39-44.
    • (1985) Can J Neurol Sci , vol.12 , Issue.1 , pp. 39-44
    • Gordon, P.A.1    Carroll, D.J.2    Etches, W.S.3    Jeffrey, V.4    Marsh, L.5    Morrice, B.L.6
  • 57
    • 0021986655 scopus 로고
    • Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs
    • 1:STN:280:DyaL2M7jvVGjsw%3D%3D 3974889 10.1212/WNL.35.3.312
    • Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology. 1985;35(3):312-9.
    • (1985) Neurology , vol.35 , Issue.3 , pp. 312-319
    • Khatri, B.O.1    McQuillen, M.P.2    Harrington, G.J.3    Schmoll, D.4    Hoffmann, R.G.5
  • 58
    • 0024436219 scopus 로고
    • Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis
    • 1:STN:280:DyaL1MzmsFGqsg%3D%3D 2549450 10.1212/WNL.39.9.1143
    • Weiner HL, Dau PC, Khatri BO, Petajan JH, Birnbaum G, McQuillen MP, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology. 1989;39(9):1143-9.
    • (1989) Neurology , vol.39 , Issue.9 , pp. 1143-1149
    • Weiner, H.L.1    Dau, P.C.2    Khatri, B.O.3    Petajan, J.H.4    Birnbaum, G.5    McQuillen, M.P.6
  • 59
    • 0025967752 scopus 로고
    • The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
    • The Canadian Cooperative Multiple Sclerosis Study Group
    • The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991;337(8739):441-6.
    • (1991) Lancet , vol.337 , Issue.8739 , pp. 441-446
  • 60
    • 23744454283 scopus 로고    scopus 로고
    • Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange
    • 16099294 10.1016/S0140-6736(05)67102-4
    • Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366(9485):579-82.
    • (2005) Lancet , vol.366 , Issue.9485 , pp. 579-582
    • Keegan, M.1    Konig, F.2    McClelland, R.3    Bruck, W.4    Morales, Y.5    Bitsch, A.6
  • 61
    • 79960186525 scopus 로고    scopus 로고
    • Beneficial plasma exchange response in central nervous system inflammatory demyelination
    • 21403003 10.1001/archneurol.2011.34
    • Magana SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011;68(7):870-8.
    • (2011) Arch Neurol , vol.68 , Issue.7 , pp. 870-878
    • Magana, S.M.1    Keegan, B.M.2    Weinshenker, B.G.3    Erickson, B.J.4    Pittock, S.J.5    Lennon, V.A.6
  • 62
    • 78650177100 scopus 로고    scopus 로고
    • The rescue effect of plasma exchange for neuromyelitis optica
    • 1:CAS:528:DC%2BC38XhvVegt73L 20888238 10.1016/j.jocn.2010.05.030
    • Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci. 2011;18(1):43-6.
    • (2011) J Clin Neurosci , vol.18 , Issue.1 , pp. 43-46
    • Wang, K.C.1    Wang, S.J.2    Lee, C.L.3    Chen, S.Y.4    Tsai, C.P.5
  • 63
    • 33846528659 scopus 로고    scopus 로고
    • Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica
    • 1:STN:280:DC%2BD2s%2Fps1KntA%3D%3D 17294622 10.1177/1352458506071174
    • Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13(1):128-32.
    • (2007) Mult Scler , vol.13 , Issue.1 , pp. 128-132
    • Watanabe, S.1    Nakashima, I.2    Misu, T.3    Miyazawa, I.4    Shiga, Y.5    Fujihara, K.6
  • 64
    • 63449095710 scopus 로고    scopus 로고
    • Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder
    • 1:STN:280:DC%2BD1M3js1OgsQ%3D%3D 19324982 10.1177/1352458508100837
    • Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15(4):487-92.
    • (2009) Mult Scler , vol.15 , Issue.4 , pp. 487-492
    • Bonnan, M.1    Valentino, R.2    Olindo, S.3    Mehdaoui, H.4    Smadja, D.5    Cabre, P.6
  • 65
    • 0029884744 scopus 로고    scopus 로고
    • Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: A randomized single-masked cross-over pilot study
    • 1:STN:280:DyaK283kvV2kuw%3D%3D 8649560 10.1212/WNL.46.6.1620
    • Sorensen PS, Wanscher B, Szpirt W, Jensen CV, Ravnborg M, Christiansen P, et al. Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology. 1996;46(6):1620-5.
    • (1996) Neurology , vol.46 , Issue.6 , pp. 1620-1625
    • Sorensen, P.S.1    Wanscher, B.2    Szpirt, W.3    Jensen, C.V.4    Ravnborg, M.5    Christiansen, P.6
  • 66
    • 78751617857 scopus 로고    scopus 로고
    • Evidence-based guideline update: Plasmapheresis in neurologic disorders. Report of the therapeutics and technology assessment Subcommittee of the American Academy of Neurology
    • 1:CAS:528:DC%2BC3MXnsFSnsA%3D%3D 21242498 10.1212/WNL.0b013e318207b1f6
    • Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the therapeutics and technology assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294-300.
    • (2011) Neurology , vol.76 , Issue.3 , pp. 294-300
    • Cortese, I.1    Chaudhry, V.2    So, Y.T.3    Cantor, F.4    Cornblath, D.R.5    Rae-Grant, A.6
  • 67
    • 0023126661 scopus 로고
    • Exacerbations of multiple sclerosis in patients treated with gamma interferon
    • 1:STN:280:DyaL2s7ntFylug%3D%3D 2882294 10.1016/S0140-6736(87)92863-7
    • Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;1(8538):893-5.
    • (1987) Lancet , vol.1 , Issue.8538 , pp. 893-895
    • Panitch, H.S.1    Hirsch, R.L.2    Haley, A.S.3    Johnson, K.P.4
  • 68
    • 0019856763 scopus 로고
    • Intrathecal interferon reduces exacerbations of multiple sclerosis
    • 1:STN:280:DyaL38%2FmtFygtA%3D%3D 6171035 10.1126/science.6171035
    • Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science. 1981;214(4524):1026-8.
    • (1981) Science , vol.214 , Issue.4524 , pp. 1026-1028
    • Jacobs, L.1    O'Malley, J.2    Freeman, A.3    Ekes, R.4
  • 69
    • 0023191664 scopus 로고
    • Systemic alpha-interferon in multiple sclerosis. Long-term patient follow-up
    • 1:STN:280:DyaL2s%2FpvFCntQ%3D%3D 3800723 10.1001/archneur.1987. 00520130047016
    • Panitch HS. Systemic alpha-interferon in multiple sclerosis. Long-term patient follow-up. Arch Neurol. 1987;44(1):61-3.
    • (1987) Arch Neurol , vol.44 , Issue.1 , pp. 61-63
    • Panitch, H.S.1
  • 70
    • 84907109913 scopus 로고
    • Suppression of experimental allergic encephalomyelitis by interferon
    • 1:CAS:528:DyaL38XkslSlsLk%3D 6178681
    • Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun. 1982;11(1):1-7.
    • (1982) Immunol Commun , vol.11 , Issue.1 , pp. 1-7
    • Abreu, S.L.1
  • 71
    • 0021953873 scopus 로고
    • Interferon in experimental autoimmune encephalomyelitis (EAE): Effects of exogeneous interferon on the antigen-enhanced adoptive transfer of EAE
    • 1:CAS:528:DyaL2MXktVCktbc%3D 2579912 10.1159/000233711
    • Abreu SL. Interferon in experimental autoimmune encephalomyelitis (EAE): effects of exogeneous interferon on the antigen-enhanced adoptive transfer of EAE. Int Arch Allergy Appl Immunol. 1985;76(4):302-7.
    • (1985) Int Arch Allergy Appl Immunol. , vol.76 , Issue.4 , pp. 302-307
    • Abreu, S.L.1
  • 72
    • 0027432017 scopus 로고
    • In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta
    • 1:STN:280:DyaK2c%2FitVansA%3D%3D 8105424 10.1212/WNL.43.10.2080
    • Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology. 1993;43(10):2080-7.
    • (1993) Neurology , vol.43 , Issue.10 , pp. 2080-2087
    • Rudick, R.A.1    Carpenter, C.S.2    Cookfair, D.L.3    Tuohy, V.K.4    Ransohoff, R.M.5
  • 73
    • 0025213264 scopus 로고
    • Interferon beta augments suppressor cell function in multiple sclerosis
    • 1:STN:280:DyaK3c7pslWnsg%3D%3D 2138445 10.1002/ana.410270219
    • Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol. 1990;27(2):207-10.
    • (1990) Ann Neurol , vol.27 , Issue.2 , pp. 207-210
    • Noronha, A.1    Toscas, A.2    Jensen, M.A.3
  • 74
    • 0022405018 scopus 로고
    • Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages
    • 1:CAS:528:DyaL2MXlt1WntrY%3D 3926890
    • Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol. 1985;135(3):1857-63.
    • (1985) J Immunol , vol.135 , Issue.3 , pp. 1857-1863
    • Ling, P.D.1    Warren, M.K.2    Vogel, S.N.3
  • 75
    • 0029091861 scopus 로고
    • Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients
    • 1:CAS:528:DyaK2MXnvFWgurw%3D 7560009 10.1016/0165-5728(95)00070-I
    • Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995;61(1):27-34.
    • (1995) J Neuroimmunol , vol.61 , Issue.1 , pp. 27-34
    • Porrini, A.M.1    Gambi, D.2    Reder, A.T.3
  • 76
    • 74249112995 scopus 로고    scopus 로고
    • Interferon-beta mechanisms of action in multiple sclerosis
    • 1:CAS:528:DC%2BD1MXhs1ait7fP 20038758 10.1212/WNL.0b013e3181c97d99
    • Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(Suppl. 1):S17-24.
    • (2010) Neurology , vol.74 , Issue.SUPPL. 1
    • Dhib-Jalbut, S.1    Marks, S.2
  • 77
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61.
    • (1993) Neurology , vol.43 , Issue.4 , pp. 655-661
  • 78
    • 0027521002 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group
    • 1:STN:280:DyaK3s3is1Sqtw%3D%3D 8469319 10.1212/WNL.43.4.662
    • Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):662-7.
    • (1993) Neurology , vol.43 , Issue.4 , pp. 662-667
    • Paty, D.W.1    Li, D.K.2
  • 79
    • 0029161628 scopus 로고
    • Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group
    • Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45(7):1277-85.
    • (1995) Neurology , vol.45 , Issue.7 , pp. 1277-1285
  • 80
    • 0008678962 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
    • 1:CAS:528:DyaK28XisFyrsLY%3D 8602746 10.1002/ana.410390304
    • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-94.
    • (1996) Ann Neurol , vol.39 , Issue.3 , pp. 285-294
    • Jacobs, L.D.1    Cookfair, D.L.2    Rudick, R.A.3    Herndon, R.M.4    Richert, J.R.5    Salazar, A.M.6
  • 81
    • 0344809968 scopus 로고    scopus 로고
    • Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. The Once Weekly Interferon for MS Study Group
    • Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology. 1999;53(4):679-86.
    • (1999) Neurology , vol.53 , Issue.4 , pp. 679-686
  • 82
    • 0345601517 scopus 로고    scopus 로고
    • Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
    • Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-504.
    • (1998) Lancet , vol.352 , Issue.9139 , pp. 1498-1504
  • 83
    • 0032864616 scopus 로고    scopus 로고
    • Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis
    • 1:CAS:528:DyaK1MXlsFWnt7Y%3D 10443885 10.1002/1531-8249(199908)46: 2<197: AID-ANA9>3.0.CO;2-P
    • Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol. 1999;46(2):197-206.
    • (1999) Ann Neurol , vol.46 , Issue.2 , pp. 197-206
    • Li, D.K.1    Paty, D.W.2
  • 84
    • 78751636602 scopus 로고    scopus 로고
    • Long-term follow-up of clinical trials of multiple sclerosis therapies
    • 1:CAS:528:DC%2BC3MXhs1yrt78%3D 21205679 10.1212/WNL.0b013e318205051d
    • Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology. 2011;76(1 Suppl. 1):S26-34.
    • (2011) Neurology , vol.76 , Issue.1 SUPPL. 1
    • Freedman, M.S.1
  • 85
    • 0035954361 scopus 로고    scopus 로고
    • PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
    • PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group
    • PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628-36.
    • (2001) Neurology , vol.56 , Issue.12 , pp. 1628-1636
  • 86
    • 77955762153 scopus 로고    scopus 로고
    • Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial
    • 1:STN:280:DC%2BC3cjktlOhsQ%3D%3D 20562430 10.1136/jnnp.2009.204123
    • Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010;81(8):907-12.
    • (2010) J Neurol Neurosurg Psychiatry , vol.81 , Issue.8 , pp. 907-912
    • Ebers, G.C.1    Traboulsee, A.2    Li, D.3    Langdon, D.4    Reder, A.T.5    Goodin, D.S.6
  • 87
    • 0034727059 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
    • 1:CAS:528:DC%2BD3cXntFOkt7k%3D 11006365 10.1056/NEJM200009283431301
    • Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904.
    • (2000) N Engl J Med , vol.343 , Issue.13 , pp. 898-904
    • Jacobs, L.D.1    Beck, R.W.2    Simon, J.H.3    Kinkel, R.P.4    Brownscheidle, C.M.5    Murray, T.J.6
  • 88
    • 6944246720 scopus 로고    scopus 로고
    • Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial
    • 1:CAS:528:DC%2BD2cXovVKrtrw%3D 15500893 10.1016/S0140-6736(04)17271-1
    • Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9444):1489-96.
    • (2004) Lancet , vol.364 , Issue.9444 , pp. 1489-1496
    • Filippi, M.1    Rovaris, M.2    Inglese, M.3    Barkhof, F.4    De Stefano, N.5    Smith, S.6
  • 89
    • 33749661011 scopus 로고    scopus 로고
    • Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
    • 1:CAS:528:DC%2BD28XhtFyqtLfL 16914693 10.1212/01.wnl.0000237641.33768.8d
    • Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-9.
    • (2006) Neurology , vol.67 , Issue.7 , pp. 1242-1249
    • Kappos, L.1    Polman, C.H.2    Freedman, M.S.3    Edan, G.4    Hartung, H.P.5    Miller, D.H.6
  • 90
    • 33645100122 scopus 로고    scopus 로고
    • IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event
    • 16436649 10.1212/01.wnl.0000200778.65597.ae 1:CAS:528: DC%2BD28Xhs1Grtb8%3D
    • Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66(5):678-84.
    • (2006) Neurology , vol.66 , Issue.5 , pp. 678-684
    • Kinkel, R.P.1    Kollman, C.2    O'Connor, P.3    Murray, T.J.4    Simon, J.5    Arnold, D.6
  • 91
    • 34547497820 scopus 로고    scopus 로고
    • Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study
    • 1:CAS:528:DC%2BD2sXosFKktLc%3D 17679016 10.1016/S0140-6736(07)61194-5
    • Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-97.
    • (2007) Lancet , vol.370 , Issue.9585 , pp. 389-397
    • Kappos, L.1    Freedman, M.S.2    Polman, C.H.3    Edan, G.4    Hartung, H.P.5    Miller, D.H.6
  • 92
    • 70449713830 scopus 로고    scopus 로고
    • Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
    • 1:CAS:528:DC%2BD1MXhsVertbbK 19748319 10.1016/S1474-4422(09)70237-6
    • Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987-97.
    • (2009) Lancet Neurol , vol.8 , Issue.11 , pp. 987-997
    • Kappos, L.1    Freedman, M.S.2    Polman, C.H.3    Edan, G.4    Hartung, H.P.5    Miller, D.H.6
  • 93
    • 83555166210 scopus 로고    scopus 로고
    • Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial
    • 1:CAS:528:DC%2BC3MXhs1CisLzO 22146409 10.1016/S1474-4422(11)70262-9
    • Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11(1):33-41.
    • (2012) Lancet Neurol , vol.11 , Issue.1 , pp. 33-41
    • Comi, G.1    De Stefano, N.2    Freedman, M.S.3    Barkhof, F.4    Polman, C.H.5    Uitdehaag, B.M.6
  • 95
    • 0032494792 scopus 로고    scopus 로고
    • Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS
    • Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352(9139):1491-7.
    • (1998) Lancet , vol.352 , Issue.9139 , pp. 1491-1497
  • 96
    • 0033472729 scopus 로고    scopus 로고
    • Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis
    • 1:CAS:528:DC%2BD3cXhsFyrtQ%3D%3D 10589537 10.1002/1531-8249(199912)46: 6<850: AID-ANA7>3.0.CO;2-Q
    • Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol. 1999;46(6):850-9.
    • (1999) Ann Neurol , vol.46 , Issue.6 , pp. 850-859
    • Miller, D.H.1    Molyneux, P.D.2    Barker, G.J.3    Macmanus, D.G.4    Moseley, I.F.5    Wagner, K.6
  • 97
    • 8844222623 scopus 로고    scopus 로고
    • Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
    • 15557491 10.1212/01.WNL.0000146958.77317.3E 1:CAS:528: DC%2BD2cXpt1eiu7Y%3D
    • Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788-95.
    • (2004) Neurology , vol.63 , Issue.10 , pp. 1788-1795
    • Panitch, H.1    Miller, A.2    Paty, D.3    Weinshenker, B.4
  • 98
    • 8844285856 scopus 로고    scopus 로고
    • Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials
    • 1:CAS:528:DC%2BD2cXpt1eiu7g%3D 15557490 10.1212/01.WNL.0000145561.08973. 4F
    • Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63(10):1779-87.
    • (2004) Neurology , vol.63 , Issue.10 , pp. 1779-1787
    • Kappos, L.1    Weinshenker, B.2    Pozzilli, C.3    Thompson, A.J.4    Dahlke, F.5    Beckmann, K.6
  • 99
    • 0035849496 scopus 로고    scopus 로고
    • Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
    • Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56(11):1496-504.
    • (2001) Neurology , vol.56 , Issue.11 , pp. 1496-1504
  • 100
    • 0037056364 scopus 로고    scopus 로고
    • Benefit of interferon beta-1a on MSFC progression in secondary progressive MS
    • 1:CAS:528:DC%2BD38XnvVSntr8%3D 12221157 10.1212/WNL.59.5.679
    • Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59(5):679-87.
    • (2002) Neurology , vol.59 , Issue.5 , pp. 679-687
    • Cohen, J.A.1    Cutter, G.R.2    Fischer, J.S.3    Goodman, A.D.4    Heidenreich, F.R.5    Kooijmans, M.F.6
  • 102
    • 0037441441 scopus 로고    scopus 로고
    • Interferon beta-1a in primary progressive multiple sclerosis
    • 1:CAS:528:DC%2BD3sXmsV2ltQ%3D%3D 12559514 10.1016/S0022-510X(02)00350-7
    • Leary SM, Thompson AJ. Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci. 2003;206(2):215-6.
    • (2003) J Neurol Sci , vol.206 , Issue.2 , pp. 215-216
    • Leary, S.M.1    Thompson, A.J.2
  • 103
    • 72449124379 scopus 로고    scopus 로고
    • A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
    • 1:CAS:528:DC%2BD1MXhsVOgsbfL 19797261 10.1177/1352458509106937
    • Montalban X, Sastre-Garriga J, Tintore M, Brieva L, Aymerich FX, Rio J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009;15(10):1195-205.
    • (2009) Mult Scler , vol.15 , Issue.10 , pp. 1195-1205
    • Montalban, X.1    Sastre-Garriga, J.2    Tintore, M.3    Brieva, L.4    Aymerich, F.X.5    Rio, J.6
  • 104
    • 81355133371 scopus 로고    scopus 로고
    • Interferon beta-1b for the treatment of primary progressive multiple sclerosis: Five-year clinical trial follow-up
    • 22084124 10.1001/archneurol.2011.241
    • Tur C, Montalban X, Tintore M, Nos C, Rio J, Aymerich FX, et al. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch Neurol. 2011;68(11):1421-7.
    • (2011) Arch Neurol , vol.68 , Issue.11 , pp. 1421-1427
    • Tur, C.1    Montalban, X.2    Tintore, M.3    Nos, C.4    Rio, J.5    Aymerich, F.X.6
  • 105
    • 2942592729 scopus 로고    scopus 로고
    • Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis
    • 1:CAS:528:DC%2BD2cXktVKgt7o%3D 15184610 10.1212/01.WNL.0000129265.73259. 9E
    • Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004;62(11):2031-7.
    • (2004) Neurology , vol.62 , Issue.11 , pp. 2031-2037
    • Malucchi, S.1    Sala, A.2    Gilli, F.3    Bottero, R.4    Di Sapio, A.5    Capobianco, M.6
  • 106
    • 22044436956 scopus 로고    scopus 로고
    • Interferon beta-1a in MS: Results following development of neutralizing antibodies in PRISMS
    • 1:CAS:528:DC%2BD2MXlsFajsLk%3D 16009884 10.1212/01.wnl.0000171748.48188. 5b
    • Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology. 2005;65(1):48-55.
    • (2005) Neurology , vol.65 , Issue.1 , pp. 48-55
    • Francis, G.S.1    Rice, G.P.2    Alsop, J.C.3
  • 107
    • 80055068683 scopus 로고    scopus 로고
    • Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome
    • 1:CAS:528:DC%2BC3MXhtFWlsrrP 21849647 10.1212/WNL.0b013e31822c90d7
    • Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, et al. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 2011;77(9):835-43.
    • (2011) Neurology , vol.77 , Issue.9 , pp. 835-843
    • Hartung, H.P.1    Freedman, M.S.2    Polman, C.H.3    Edan, G.4    Kappos, L.5    Miller, D.H.6
  • 108
    • 84856734786 scopus 로고    scopus 로고
    • Neutralizing antibodies to interferon beta-1b multiple sclerosis: A clinico-radiographic paradox in the beyond trial
    • 1:CAS:528:DC%2BC38XltFKjsLo%3D 21952094 10.1177/1352458511418629
    • Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012;18(2):181-95.
    • (2012) Mult Scler , vol.18 , Issue.2 , pp. 181-195
    • Goodin, D.S.1    Hartung, H.P.2    O'Connor, P.3    Filippi, M.4    Arnason, B.5    Comi, G.6
  • 109
    • 70449449076 scopus 로고    scopus 로고
    • Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study
    • 1:CAS:528:DC%2BD1MXhtlCmsrjK 19884577 10.1212/WNL.0b013e3181bf98db
    • Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology. 2009;73(18):1493-500.
    • (2009) Neurology , vol.73 , Issue.18 , pp. 1493-1500
    • Pachner, A.R.1    Warth, J.D.2    Pace, A.3    Goelz, S.4
  • 110
    • 0037180479 scopus 로고    scopus 로고
    • Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial
    • 1:CAS:528:DC%2BD38XosVCmtro%3D 12451188 10.1212/01.WNL.0000034080.43681. DA
    • Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59(10):1496-506.
    • (2002) Neurology , vol.59 , Issue.10 , pp. 1496-1506
    • Panitch, H.1    Goodin, D.S.2    Francis, G.3    Chang, P.4    Coyle, P.K.5    O'Connor, P.6
  • 111
    • 36849035929 scopus 로고    scopus 로고
    • Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis
    • 1:CAS:528:DC%2BD2sXhtlakt7jI 18035202 10.1016/j.clinthera.2007.09.025
    • Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29(9):2031-48.
    • (2007) Clin Ther , vol.29 , Issue.9 , pp. 2031-2048
    • Schwid, S.R.1    Panitch, H.S.2
  • 112
    • 0037181634 scopus 로고    scopus 로고
    • Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)
    • 1:CAS:528:DC%2BD38Xjt1SktrY%3D 11988242 10.1016/S0140-6736(02)08430-1
    • Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-60.
    • (2002) Lancet , vol.359 , Issue.9316 , pp. 1453-1460
    • Durelli, L.1    Verdun, E.2    Barbero, P.3    Bergui, M.4    Versino, E.5    Ghezzi, A.6
  • 113
    • 70449360324 scopus 로고    scopus 로고
    • New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate
    • 1:STN:280:DC%2BD1Mjmt1Shtg%3D%3D 19687024 10.1136/jnnp.2008.171090
    • Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry. 2009;80(12):1337-43.
    • (2009) J Neurol Neurosurg Psychiatry , vol.80 , Issue.12 , pp. 1337-1343
    • Cadavid, D.1    Cheriyan, J.2    Skurnick, J.3    Lincoln, J.A.4    Wolansky, L.J.5    Cook, S.D.6
  • 114
    • 33646117499 scopus 로고    scopus 로고
    • A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
    • 1:CAS:528:DC%2BD28XislWlu7k%3D 16510769 10.1212/01.wnl.0000204018.52311. ec
    • Koch-Henriksen N, Sorensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006;66(7):1056-60.
    • (2006) Neurology , vol.66 , Issue.7 , pp. 1056-1060
    • Koch-Henriksen, N.1    Sorensen, P.S.2    Christensen, T.3    Frederiksen, J.4    Ravnborg, M.5    Jensen, K.6
  • 115
    • 69949098534 scopus 로고    scopus 로고
    • 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study
    • 19729344 10.1016/S1474-4422(09)70226-1 1:CAS:528:DC%2BD1MXht1Kitr7O
    • O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-97.
    • (2009) Lancet Neurol , vol.8 , Issue.10 , pp. 889-897
    • O'Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Goodin, D.6
  • 116
    • 51449101000 scopus 로고    scopus 로고
    • Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial
    • 1:CAS:528:DC%2BD1cXht1enu7%2FN 18789766 10.1016/S1474-4422(08)70200-X
    • Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-14.
    • (2008) Lancet Neurol , vol.7 , Issue.10 , pp. 903-914
    • Mikol, D.D.1    Barkhof, F.2    Chang, P.3    Coyle, P.K.4    Jeffery, D.R.5    Schwid, S.R.6
  • 117
    • 0015795775 scopus 로고
    • Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen
    • 1:CAS:528:DyaE3sXltFersbs%3D 4128127 10.1002/eji.1830030505
    • Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol. 1973;3(5):273-9.
    • (1973) Eur J Immunol , vol.3 , Issue.5 , pp. 273-279
    • Teitelbaum, D.1    Webb, C.2    Meshorer, A.3    Arnon, R.4    Sela, M.5
  • 118
    • 0023248694 scopus 로고
    • A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
    • 1:STN:280:DyaL2s3oslSqtA%3D%3D 3302705 10.1056/NEJM198708133170703
    • Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987;317(7):408-14.
    • (1987) N Engl J Med , vol.317 , Issue.7 , pp. 408-414
    • Bornstein, M.B.1    Miller, A.2    Slagle, S.3    Weitzman, M.4    Crystal, H.5    Drexler, E.6
  • 119
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group
    • 1:STN:280:DyaK2Mzkt1eqtQ%3D%3D 7617181 10.1212/WNL.45.7.1268
    • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
    • (1995) Neurology , vol.45 , Issue.7 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3    Ford, C.C.4    Goldstein, J.5    Lisak, R.P.6
  • 120
    • 0035091667 scopus 로고    scopus 로고
    • European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group
    • 1:CAS:528:DC%2BD3MXisVyqtL0%3D 11261502 10.1002/ana.64
    • Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290-7.
    • (2001) Ann Neurol , vol.49 , Issue.3 , pp. 290-297
    • Comi, G.1    Filippi, M.2    Wolinsky, J.S.3
  • 121
    • 32544449771 scopus 로고    scopus 로고
    • Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: A multicentre, double-blind, randomised, placebo-controlled study
    • 1:CAS:528:DC%2BD28XisF2qsbo%3D 16488376 10.1016/S1474-4422(06)70327-1
    • Filippi M, Wolinsky JS, Comi G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol. 2006;5(3):213-20.
    • (2006) Lancet Neurol , vol.5 , Issue.3 , pp. 213-220
    • Filippi, M.1    Wolinsky, J.S.2    Comi, G.3
  • 122
    • 79551484331 scopus 로고    scopus 로고
    • Phase III dose-comparison study of glatiramer acetate for multiple sclerosis
    • 1:CAS:528:DC%2BC3MXisVCis7k%3D 21280077 10.1002/ana.22316
    • Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011;69(1):75-82.
    • (2011) Ann Neurol , vol.69 , Issue.1 , pp. 75-82
    • Comi, G.1    Cohen, J.A.2    Arnold, D.L.3    Wynn, D.4    Filippi, M.5
  • 123
    • 46749113012 scopus 로고    scopus 로고
    • Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    • 18208875 10.1177/1352458507085029
    • Miller A, Spada V, Beerkircher D, Kreitman RR. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2008;14(4):494-9.
    • (2008) Mult Scler , vol.14 , Issue.4 , pp. 494-499
    • Miller, A.1    Spada, V.2    Beerkircher, D.3    Kreitman, R.R.4
  • 124
    • 77649337857 scopus 로고    scopus 로고
    • Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy
    • 1:CAS:528:DC%2BC3cXjtVWjs70%3D 20153903 10.1016/j.jneuroim.2010.01.009
    • Karussis D, Teitelbaum D, Sicsic C, Brenner T. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol. 2010;220(1-2):125-30.
    • (2010) J Neuroimmunol , vol.220 , Issue.1-2 , pp. 125-130
    • Karussis, D.1    Teitelbaum, D.2    Sicsic, C.3    Brenner, T.4
  • 125
    • 70350786389 scopus 로고    scopus 로고
    • Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial
    • 1:CAS:528:DC%2BD1MXhtlCmt7zN 19815268 10.1016/S0140-6736(09)61259-9
    • Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503- 11.
    • (2009) Lancet , vol.374 , Issue.9700 , pp. 1503-1511
    • Comi, G.1    Martinelli, V.2    Rodegher, M.3    Moiola, L.4    Bajenaru, O.5    Carra, A.6
  • 126
    • 33846833929 scopus 로고    scopus 로고
    • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
    • 1:CAS:528:DC%2BD2sXitlyjt78%3D 17262850 10.1002/ana.21079
    • Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61(1):14-24.
    • (2007) Ann Neurol , vol.61 , Issue.1 , pp. 14-24
    • Wolinsky, J.S.1    Narayana, P.A.2    O'Connor, P.3    Coyle, P.K.4    Ford, C.5    Johnson, K.6
  • 127
    • 42149098368 scopus 로고    scopus 로고
    • Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: Multicenter study
    • 1:STN:280:DC%2BD1c7ntFamtQ%3D%3D 17881390 10.1177/1352458507079907
    • Sajja BR, Narayana PA, Wolinsky JS, Ahn CW. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler. 2008;14(1):73-80.
    • (2008) Mult Scler , vol.14 , Issue.1 , pp. 73-80
    • Sajja, B.R.1    Narayana, P.A.2    Wolinsky, J.S.3    Ahn, C.W.4
  • 128
    • 0026471169 scopus 로고
    • Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis
    • 1:STN:280:DyaK3s%2FotVClug%3D%3D 1449400 10.1001/archneur.1992. 00530360031013
    • Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol. 1992;49(12):1233-6.
    • (1992) Arch Neurol , vol.49 , Issue.12 , pp. 1233-1236
    • Achiron, A.1    Pras, E.2    Gilad, R.3    Ziv, I.4    Mandel, M.5    Gordon, C.R.6
  • 129
    • 0026896848 scopus 로고
    • Improvement of motor function in multiple sclerosis by use of protopam chloride
    • 1:STN:280:DyaK3s%2FjsVGiug%3D%3D 1357924
    • Cook AW, Nidzgorski F, Oygar A. Improvement of motor function in multiple sclerosis by use of protopam chloride. Acupunct Electrother Res. 1992;17(3):177-93.
    • (1992) Acupunct Electrother Res , vol.17 , Issue.3 , pp. 177-193
    • Cook, A.W.1    Nidzgorski, F.2    Oygar, A.3
  • 130
    • 0031460587 scopus 로고    scopus 로고
    • Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: A clinical and MRI based study
    • 1:CAS:528:DyaK1cXoslemug%3D%3D 9493636 10.1177/135245859700300602
    • Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler. 1997;3(6):370-6.
    • (1997) Mult Scler , vol.3 , Issue.6 , pp. 370-376
    • Francis, G.S.1    Freedman, M.S.2    Antel, J.P.3
  • 131
    • 0028291547 scopus 로고
    • Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis
    • 1:STN:280:DyaK2c3ps1SksA%3D%3D 8024266 10.1002/ana.410360115
    • Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol. 1994;36(1):76-82.
    • (1994) Ann Neurol , vol.36 , Issue.1 , pp. 76-82
    • Arnold, D.L.1    Riess, G.T.2    Matthews, P.M.3    Francis, G.S.4    Collins, D.L.5    Wolfson, C.6
  • 133
    • 0030799818 scopus 로고    scopus 로고
    • Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analyses of the Austrian Immunoglobulin in MS study
    • 1:CAS:528:DyaK2sXmtlyqtb0%3D 9291168 10.1177/135245859700300214
    • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. Mult Scler. 1997;3(2):137-41.
    • (1997) Mult Scler , vol.3 , Issue.2 , pp. 137-141
    • Fazekas, F.1    Deisenhammer, F.2    Strasser-Fuchs, S.3    Nahler, G.4    Mamoli, B.5
  • 134
    • 0031057970 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group
    • 1:CAS:528:DyaK2sXhvFOlsb4%3D 9057729 10.1016/S0140-6736(96)09377-4
    • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997;349(9052):589-93.
    • (1997) Lancet , vol.349 , Issue.9052 , pp. 589-593
    • Fazekas, F.1    Deisenhammer, F.2    Strasser-Fuchs, S.3    Nahler, G.4    Mamoli, B.5
  • 135
    • 4644250609 scopus 로고    scopus 로고
    • Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial
    • 1:CAS:528:DC%2BD2cXnvVOiu7g%3D 15451222 10.1016/S0140-6736(04)17101-8
    • Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004;364(9440):1149-56.
    • (2004) Lancet , vol.364 , Issue.9440 , pp. 1149-1156
    • Hommes, O.R.1    Sorensen, P.S.2    Fazekas, F.3    Enriquez, M.M.4    Koelmel, H.W.5    Fernandez, O.6
  • 136
    • 39549098027 scopus 로고    scopus 로고
    • Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: A randomized placebo controlled multicentre study
    • 1:CAS:528:DC%2BD1cXmtV2rtbk%3D 17623736 10.1177/1352458507078400
    • Pohlau D, Przuntek H, Sailer M, Bethke F, Koehler J, Konig N, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler. 2007;13(9):1107-17.
    • (2007) Mult Scler , vol.13 , Issue.9 , pp. 1107-1117
    • Pohlau, D.1    Przuntek, H.2    Sailer, M.3    Bethke, F.4    Koehler, J.5    Konig, N.6
  • 137
    • 0036833722 scopus 로고    scopus 로고
    • No difference in efficacy of two different doses of intravenous immunoglobulins in MS: Clinical and MRI assessment
    • 1:STN:280:DC%2BD38npt1Cqtg%3D%3D 12453070 10.1046/j.1468-1331.2002.00500. x
    • Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol. 2002;9(6):565-72.
    • (2002) Eur J Neurol , vol.9 , Issue.6 , pp. 565-572
    • Lewanska, M.1    Siger-Zajdel, M.2    Selmaj, K.3
  • 138
    • 50549098795 scopus 로고    scopus 로고
    • Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial
    • 1:CAS:528:DC%2BD1cXosFSrsr8%3D 18645164 10.1212/01.wnl.0000318281.98220. 6f
    • Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008;71(4):265-71.
    • (2008) Neurology , vol.71 , Issue.4 , pp. 265-271
    • Fazekas, F.1    Lublin, F.D.2    Li, D.3    Freedman, M.S.4    Hartung, H.P.5    Rieckmann, P.6
  • 139
    • 0031844370 scopus 로고    scopus 로고
    • Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
    • 1:STN:280:DyaK1c3lsFCisQ%3D%3D 9595974 10.1212/WNL.50.5.1273
    • Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998;50(5):1273-81.
    • (1998) Neurology , vol.50 , Issue.5 , pp. 1273-1281
    • Sorensen, P.S.1    Wanscher, B.2    Jensen, C.V.3    Schreiber, K.4    Blinkenberg, M.5    Ravnborg, M.6
  • 141
    • 0035849518 scopus 로고    scopus 로고
    • A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
    • 1:CAS:528:DC%2BD3MXkvVOlsLc%3D 11402108 10.1212/WNL.56.11.1514
    • Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56(11):1514-22.
    • (2001) Neurology , vol.56 , Issue.11 , pp. 1514-1522
    • Noseworthy, J.H.1    O'Brien, P.C.2    Petterson, T.M.3    Weis, J.4    Stevens, L.5    Peterson, W.K.6
  • 142
    • 0031911494 scopus 로고    scopus 로고
    • Intravenous immunoglobulin treatment in multiple sclerosis: Effect on relapses
    • 1:CAS:528:DyaK1cXhsl2js7c%3D 9484361 10.1212/WNL.50.2.398
    • Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology. 1998;50(2):398-402.
    • (1998) Neurology , vol.50 , Issue.2 , pp. 398-402
    • Achiron, A.1    Gabbay, U.2    Gilad, R.3    Hassin-Baer, S.4    Barak, Y.5    Gornish, M.6
  • 143
    • 68949125991 scopus 로고
    • Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group
    • Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet. 1988;2(8604):179-83.
    • (1988) Lancet , vol.2 , Issue.8604 , pp. 179-183
  • 144
    • 0026098973 scopus 로고
    • The efficacy of azathioprine in relapsing-remitting multiple sclerosis
    • 1:STN:280:DyaK3M%2FovVSrsg%3D%3D 1985289 10.1212/WNL.41.1.20
    • Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology. 1991;41(1):20-5.
    • (1991) Neurology , vol.41 , Issue.1 , pp. 20-25
    • Goodkin, D.E.1    Bailly, R.C.2    Teetzen, M.L.3    Hertsgaard, D.4    Beatty, W.W.5
  • 145
    • 0027180925 scopus 로고
    • A double blind study on azathioprine efficacy in multiple sclerosis: Final report
    • 1:STN:280:DyaK3szhs1Wjtw%3D%3D 8326334 10.1007/BF00838165
    • Milanese C, La Mantia L, Salmaggi A, Eoli M. A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol. 1993;240(5):295-8.
    • (1993) J Neurol , vol.240 , Issue.5 , pp. 295-298
    • Milanese, C.1    La Mantia, L.2    Salmaggi, A.3    Eoli, M.4
  • 146
    • 0024462396 scopus 로고
    • A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis
    • 1:STN:280:DyaL1MzksVequg%3D%3D 2668784 10.1212/WNL.39.8.1018
    • Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology. 1989;39(8):1018-26.
    • (1989) Neurology , vol.39 , Issue.8 , pp. 1018-1026
    • Ellison, G.W.1    Myers, L.W.2    Mickey, M.R.3    Graves, M.C.4    Tourtellotte, W.W.5    Syndulko, K.6
  • 148
    • 28944446244 scopus 로고    scopus 로고
    • Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging
    • 16344342 10.1001/archneur.62.12.1843
    • Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicano G, Konze A, et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol. 2005;62(12):1843-7.
    • (2005) Arch Neurol , vol.62 , Issue.12 , pp. 1843-1847
    • Massacesi, L.1    Parigi, A.2    Barilaro, A.3    Repice, A.M.4    Pellicano, G.5    Konze, A.6
  • 149
    • 1642281053 scopus 로고    scopus 로고
    • The risk of cancer from azathioprine as a treatment for multiple sclerosis [letter]
    • 1:STN:280:DC%2BD2c%2FkvVCnsQ%3D%3D 14748776 10.1046/j.1351-5101.2003. 00721.x
    • Taylor L, Hughes RA, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis [letter]. Eur J Neurol. 2004;11(2):141.
    • (2004) Eur J Neurol , vol.11 , Issue.2 , pp. 141
    • Taylor, L.1    Hughes, R.A.2    McPherson, K.3
  • 150
    • 69549101754 scopus 로고    scopus 로고
    • Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis
    • 1:CAS:528:DC%2BD1MXhtF2jtb7J 19465443 10.1177/1352458509105229
    • Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler. 2009;15(8):965-76.
    • (2009) Mult Scler , vol.15 , Issue.8 , pp. 965-976
    • Havrdova, E.1    Zivadinov, R.2    Krasensky, J.3    Dwyer, M.G.4    Novakova, I.5    Dolezal, O.6
  • 151
    • 0032528896 scopus 로고    scopus 로고
    • Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
    • 1:CAS:528:DyaK1cXlsFartbs%3D 9710434 10.1172/JCI3125
    • Comabella M, Balashov K, Issazadeh S, Smith D, Weiner HL, Khoury SJ. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest. 1998;102(4):671-8.
    • (1998) J Clin Invest , vol.102 , Issue.4 , pp. 671-678
    • Comabella, M.1    Balashov, K.2    Issazadeh, S.3    Smith, D.4    Weiner, H.L.5    Khoury, S.J.6
  • 152
    • 0030767497 scopus 로고    scopus 로고
    • Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia
    • 1:CAS:528:DyaK2sXmt1yjtb4%3D 9307252 10.1002/ana.410420307
    • Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol. 1997;42(3):313-8.
    • (1997) Ann Neurol , vol.42 , Issue.3 , pp. 313-318
    • Smith, D.R.1    Balashov, K.E.2    Hafler, D.A.3    Khoury, S.J.4    Weiner, H.L.5
  • 154
    • 0029037063 scopus 로고
    • Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: Emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis
    • 1:STN:280:DyaK2M3otlWltg%3D%3D 7762914
    • Boumpas DT, Fessler BJ, Austin HA 3rd. Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med. 1995;123(1):42-53.
    • (1995) Ann Intern Med , vol.123 , Issue.1 , pp. 42-53
    • Boumpas, D.T.1    Fessler, B.J.2    Austin III, H.A.3
  • 155
    • 0016754809 scopus 로고
    • Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone
    • 1:STN:280:DyaE28%2Fgt1Sksg%3D%3D 1157430 10.1016/S0303-8467(75)80007-2
    • Hommes OR, Prick JJ, Lamers KJ. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg. 1975;78(1):59-72.
    • (1975) Clin Neurol Neurosurg , vol.78 , Issue.1 , pp. 59-72
    • Hommes, O.R.1    Prick, J.J.2    Lamers, K.J.3
  • 156
    • 0027196941 scopus 로고
    • Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
    • 1:STN:280:DyaK3s3mtFKisw%3D%3D 8388090 10.1212/WNL.43.5.910
    • Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993;43(5):910-8.
    • (1993) Neurology , vol.43 , Issue.5 , pp. 910-918
    • Weiner, H.L.1    Mackin, G.A.2    Orav, E.J.3    Hafler, D.A.4    Dawson, D.M.5    Lapierre, Y.6
  • 157
    • 0033391669 scopus 로고    scopus 로고
    • Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: Response to therapy is linked to the duration of progressive disease
    • 1:CAS:528:DC%2BD3cXks1OltA%3D%3D 10618696
    • Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/ methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999;5(6):403-9.
    • (1999) Mult Scler , vol.5 , Issue.6 , pp. 403-409
    • Hohol, M.J.1    Olek, M.J.2    Orav, E.J.3    Stazzone, L.4    Hafler, D.A.5    Khoury, S.J.6
  • 158
    • 17844374075 scopus 로고    scopus 로고
    • Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy
    • 1:CAS:528:DC%2BD3MXlvVKht7w%3D 11475443
    • Khan OA, Zvartau-Hind M, Caon C, Din MU, Cochran M, Lisak D, et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler. 2001;7(3):185-8.
    • (2001) Mult Scler , vol.7 , Issue.3 , pp. 185-188
    • Khan, O.A.1    Zvartau-Hind, M.2    Caon, C.3    Din, M.U.4    Cochran, M.5    Lisak, D.6
  • 159
    • 0041846718 scopus 로고    scopus 로고
    • Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis
    • 1:CAS:528:DC%2BD3sXnsVSlurw%3D 12883926 10.1007/s00415-003-1089-x
    • Perini P, Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol. 2003;250(7):834-8.
    • (2003) J Neurol , vol.250 , Issue.7 , pp. 834-838
    • Perini, P.1    Gallo, P.2
  • 160
    • 10744219843 scopus 로고    scopus 로고
    • Treatment of progressive forms of multiple sclerosis by cyclophosphamide: A cohort study of 490 patients
    • 1:CAS:528:DC%2BD2cXpsV2itw%3D%3D 14759636 10.1016/j.jns.2003.11.004
    • Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci. 2004;218(1-2):73-7.
    • (2004) J Neurol Sci , vol.218 , Issue.1-2 , pp. 73-77
    • Zephir, H.1    De Seze, J.2    Duhamel, A.3    Debouverie, M.4    Hautecoeur, P.5    Lebrun, C.6
  • 161
    • 14044250814 scopus 로고    scopus 로고
    • Multiple sclerosis: Long-term remission after a high dose of cyclophosphamide
    • 15691289 10.1111/j.1600-0404.2005.00340.x
    • de Bittencourt PR, Gomes-da-Silva MM. Multiple sclerosis: long-term remission after a high dose of cyclophosphamide. Acta Neurol Scand. 2005;111(3):195-8.
    • (2005) Acta Neurol Scand , vol.111 , Issue.3 , pp. 195-198
    • De Bittencourt, P.R.1    Gomes-Da-Silva, M.M.2
  • 162
    • 33749627690 scopus 로고    scopus 로고
    • High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis
    • 16908728 10.1001/archneur.63.10.noc60076
    • Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol. 2006;63(10):1388-93.
    • (2006) Arch Neurol , vol.63 , Issue.10 , pp. 1388-1393
    • Gladstone, D.E.1    Zamkoff, K.W.2    Krupp, L.3    Peyster, R.4    Sibony, P.5    Christodoulou, C.6
  • 163
    • 25844530825 scopus 로고    scopus 로고
    • A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta
    • 1:CAS:528:DC%2BD2MXhtFGlsb7E 16193896 10.1191/1352458505ms1210oa
    • Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler. 2005;11(5):573-82.
    • (2005) Mult Scler , vol.11 , Issue.5 , pp. 573-582
    • Smith, D.R.1    Weinstock-Guttman, B.2    Cohen, J.A.3    Wei, X.4    Gutmann, C.5    Bakshi, R.6
  • 164
    • 12844251832 scopus 로고    scopus 로고
    • Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta
    • 1:CAS:528:DC%2BD2MXisVehsLg%3D 15645351 10.1007/s00415-004-0581-2
    • Patti F, Reggio E, Palermo F, Fiorilla T, Politi G, Nicoletti A, et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol. 2004;251(12):1502-6.
    • (2004) J Neurol , vol.251 , Issue.12 , pp. 1502-1506
    • Patti, F.1    Reggio, E.2    Palermo, F.3    Fiorilla, T.4    Politi, G.5    Nicoletti, A.6
  • 165
    • 10944231932 scopus 로고    scopus 로고
    • Mechanism of action of mitoxantrone
    • 1:CAS:528:DC%2BD2MXitFGhtro%3D 15623664 10.1212/WNL.63.12-suppl-6.S15
    • Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 Suppl. 6):S15-8.
    • (2004) Neurology , vol.63 , Issue.12 SUPPL. 6
    • Fox, E.J.1
  • 166
    • 8044242916 scopus 로고    scopus 로고
    • Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
    • 1:STN:280:DyaK2s3gtlagtQ%3D%3D 9050955 10.1007/s004150050066
    • Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997;244(3):153-9.
    • (1997) J Neurol , vol.244 , Issue.3 , pp. 153-159
    • Millefiorini, E.1    Gasperini, C.2    Pozzilli, C.3    D'Andrea, F.4    Bastianello, S.5    Trojano, M.6
  • 167
    • 0031040238 scopus 로고    scopus 로고
    • Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria
    • 1:STN:280:DyaK2s3gtVyrsg%3D%3D 9048709 10.1136/jnnp.62.2.112
    • Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62(2):112-8.
    • (1997) J Neurol Neurosurg Psychiatry , vol.62 , Issue.2 , pp. 112-118
    • Edan, G.1    Miller, D.2    Clanet, M.3    Confavreux, C.4    Lyon-Caen, O.5    Lubetzki, C.6
  • 168
    • 0035707562 scopus 로고    scopus 로고
    • A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis
    • 11851027
    • van de Wyngaert FA, Beguin C, D'Hooghe MB, Dooms G, Lissoir F, Carton H, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg. 2001;101(4):210-6.
    • (2001) Acta Neurol Belg , vol.101 , Issue.4 , pp. 210-216
    • Van De Wyngaert, F.A.1    Beguin, C.2    D'Hooghe, M.B.3    Dooms, G.4    Lissoir, F.5    Carton, H.6
  • 169
    • 0037153729 scopus 로고    scopus 로고
    • Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial
    • 12504397 10.1016/S0140-6736(02)12023-X
    • Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-25.
    • (2002) Lancet , vol.360 , Issue.9350 , pp. 2018-2025
    • Hartung, H.P.1    Gonsette, R.2    Konig, N.3    Kwiecinski, H.4    Guseo, A.5    Morrissey, S.P.6
  • 170
    • 33645563825 scopus 로고    scopus 로고
    • Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: A descriptive analysis of 100 consecutive patients
    • 10.1016/S0035-3787(06)74998-0
    • Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Edan G. Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients. Rev Neurol (Paris). 2006;162(2):185-94.
    • (2006) Rev Neurol (Paris) , vol.162 , Issue.2 , pp. 185-194
    • Le Page, E.1    Leray, E.2    Taurin, G.3    Coustans, M.4    Chaperon, J.5    Edan, G.6
  • 171
    • 20144385804 scopus 로고    scopus 로고
    • A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging
    • 1:CAS:528:DC%2BD2MXlslKntLY%3D 15957510 10.1191/1352458505ms1154oa
    • Jeffery DR, Chepuri N, Durden D, Burdette J. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler. 2005;11(3):296-301.
    • (2005) Mult Scler , vol.11 , Issue.3 , pp. 296-301
    • Jeffery, D.R.1    Chepuri, N.2    Durden, D.3    Burdette, J.4
  • 172
    • 33749432012 scopus 로고    scopus 로고
    • Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
    • 1:CAS:528:DC%2BD2sXls12rsg%3D%3D 16990994 10.1007/s00415-006-0178-z
    • Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol. 2006;253(9):1160-4.
    • (2006) J Neurol , vol.253 , Issue.9 , pp. 1160-1164
    • Ramtahal, J.1    Jacob, A.2    Das, K.3    Boggild, M.4
  • 173
    • 77749277178 scopus 로고    scopus 로고
    • Methotrexate: How does it really work?
    • 1:CAS:528:DC%2BC3cXis1ygt7w%3D 20197777 10.1038/nrrheum.2010.5
    • Chan ES, Cronstein BN. Methotrexate: how does it really work? Nat Rev Rheumatol. 2010;6(3):175-8.
    • (2010) Nat Rev Rheumatol , vol.6 , Issue.3 , pp. 175-178
    • Chan, E.S.1    Cronstein, B.N.2
  • 174
    • 33746488183 scopus 로고    scopus 로고
    • A systematic review of oral methotrexate for multiple sclerosis
    • 1:CAS:528:DC%2BD28Xos1yqtr0%3D 16900766 10.1191/1352458506ms1299oa
    • Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler. 2006;12(4):507-10.
    • (2006) Mult Scler , vol.12 , Issue.4 , pp. 507-510
    • Gray, O.M.1    McDonnell, G.V.2    Forbes, R.B.3
  • 175
    • 0028906384 scopus 로고
    • Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
    • 1:STN:280:DyaK2M7hvVSgsQ%3D%3D 7818255 10.1002/ana.410370108
    • Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37(1):30-40.
    • (1995) Ann Neurol , vol.37 , Issue.1 , pp. 30-40
    • Goodkin, D.E.1    Rudick, R.A.2    Vanderbrug Medendorp, S.3    Daughtry, M.M.4    Schwetz, K.M.5    Fischer, J.6
  • 176
    • 0027482084 scopus 로고
    • Low dose oral methotrexate treatment of multiple sclerosis: A pilot study
    • 1:STN:280:DyaK2c%2FksFOiug%3D%3D 8229034 10.1136/jnnp.56.11.1217
    • Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 1993;56(11):1217-8.
    • (1993) J Neurol Neurosurg Psychiatry , vol.56 , Issue.11 , pp. 1217-1218
    • Currier, R.D.1    Haerer, A.F.2    Meydrech, E.F.3
  • 177
    • 78549277149 scopus 로고    scopus 로고
    • Intrathecal methotrexate treatment in multiple sclerosis
    • 1:CAS:528:DC%2BC3cXhsVWqsrfF 20532907 10.1007/s00415-010-5614-4
    • Sadiq SA, Simon EV, Puccio LM. Intrathecal methotrexate treatment in multiple sclerosis. J Neurol. 2010;257(11):1806-11.
    • (2010) J Neurol , vol.257 , Issue.11 , pp. 1806-1811
    • Sadiq, S.A.1    Simon, E.V.2    Puccio, L.M.3
  • 178
    • 0025345601 scopus 로고
    • A randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group
    • Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis 10.1002/ana.410270603
    • Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis. A randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann Neurol. 1990;27(6):591-605.
    • (1990) Ann Neurol , vol.27 , Issue.6 , pp. 591-605
  • 179
    • 79551579477 scopus 로고    scopus 로고
    • Cladribine: Mode of action and implications for treatment of multiple sclerosis
    • 1:CAS:528:DC%2BC3MXnsVaqtw%3D%3D 21242742 10.1097/WNF.0b013e318204cd90
    • Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28-35.
    • (2011) Clin Neuropharmacol , vol.34 , Issue.1 , pp. 28-35
    • Leist, T.P.1    Weissert, R.2
  • 180
    • 0028264426 scopus 로고
    • Cladribine in treatment of chronic progressive multiple sclerosis
    • 1:STN:280:DyaK2c3osFKnsg%3D%3D 7912347 10.1016/S0140-6736(94)91046-4
    • Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994;344(8914):9-13.
    • (1994) Lancet , vol.344 , Issue.8914 , pp. 9-13
    • Sipe, J.C.1    Romine, J.S.2    Koziol, J.A.3    McMillan, R.4    Zyroff, J.5    Beutler, E.6
  • 181
    • 0029983154 scopus 로고    scopus 로고
    • The treatment of chronic progressive multiple sclerosis with cladribine
    • 1:CAS:528:DyaK28Xht1entLk%3D 8643695 10.1073/pnas.93.4.1716
    • Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA. 1996;93(4):1716-20.
    • (1996) Proc Natl Acad Sci USA , vol.93 , Issue.4 , pp. 1716-1720
    • Beutler, E.1    Sipe, J.C.2    Romine, J.S.3    Koziol, J.A.4    McMillan, R.5    Zyroff, J.6
  • 182
    • 0032908474 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
    • 1:CAS:528:DyaK1MXms1OrsQ%3D%3D 9893155 10.1046/j.1525-1381.1999.09115.x
    • Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys. 1999;111(1):35-44.
    • (1999) Proc Assoc Am Phys , vol.111 , Issue.1 , pp. 35-44
    • Romine, J.S.1    Sipe, J.C.2    Koziol, J.A.3    Zyroff, J.4    Beutler, E.5
  • 183
    • 76149083915 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
    • 1:CAS:528:DC%2BC3cXhvVaitr0%3D 20089960 10.1056/NEJMoa0902533
    • Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-26.
    • (2010) N Engl J Med , vol.362 , Issue.5 , pp. 416-426
    • Giovannoni, G.1    Comi, G.2    Cook, S.3    Rammohan, K.4    Rieckmann, P.5    Soelberg Sorensen, P.6
  • 184
    • 79952735730 scopus 로고    scopus 로고
    • Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis
    • 1:CAS:528:DC%2BC3MXjs12jtLY%3D 21397565 10.1016/S1474-4422(11)70023-0
    • Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329-37.
    • (2011) Lancet Neurol , vol.10 , Issue.4 , pp. 329-337
    • Giovannoni, G.1    Cook, S.2    Rammohan, K.3    Rieckmann, P.4    Sorensen, P.S.5    Vermersch, P.6
  • 185
    • 0034935149 scopus 로고    scopus 로고
    • Mycophenolate-mofetil in the treatment of refractory multiple sclerosis
    • 1:STN:280:DC%2BD3MritFWktw%3D%3D 11569905 10.1007/s004150170122
    • Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol. 2001;248(8):713-4.
    • (2001) J Neurol , vol.248 , Issue.8 , pp. 713-714
    • Ahrens, N.1    Salama, A.2    Haas, J.3
  • 186
    • 2342634617 scopus 로고    scopus 로고
    • Mycophenolate mofetil in multiple sclerosis
    • 1:CAS:528:DC%2BD2cXks1Sgtro%3D 15252268 10.1097/00002826-200403000-00006
    • Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol. 2004;27(2):80-3.
    • (2004) Clin Neuropharmacol , vol.27 , Issue.2 , pp. 80-83
    • Frohman, E.M.1    Brannon, K.2    Racke, M.K.3    Hawker, K.4
  • 187
    • 33846165804 scopus 로고    scopus 로고
    • Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis
    • 1:STN:280:DC%2BD2s%2FivVKiug%3D%3D 17222119 10.1111/j.1468-1331.2006. 01562.x
    • Vermersch P, Waucquier N, Michelin E, Bourteel H, Stojkovic T, Ferriby D, et al. Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol. 2007;14(1):85-9.
    • (2007) Eur J Neurol , vol.14 , Issue.1 , pp. 85-89
    • Vermersch, P.1    Waucquier, N.2    Michelin, E.3    Bourteel, H.4    Stojkovic, T.5    Ferriby, D.6
  • 188
    • 70349150578 scopus 로고    scopus 로고
    • Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients
    • 19752302 10.1001/archneurol.2009.175
    • Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128-33.
    • (2009) Arch Neurol , vol.66 , Issue.9 , pp. 1128-1133
    • Jacob, A.1    Matiello, M.2    Weinshenker, B.G.3    Wingerchuk, D.M.4    Lucchinetti, C.5    Shuster, E.6
  • 189
    • 0028609529 scopus 로고
    • Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial
    • 1:STN:280:DyaK2M3ptVKisA%3D%3D 7539635 10.3109/08916939409009536
    • Lemster B, Huang LL, Irish W, Woo J, Carroll PB, Abu-Elmagd K, et al. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity. 1994;19(2):89-98.
    • (1994) Autoimmunity , vol.19 , Issue.2 , pp. 89-98
    • Lemster, B.1    Huang, L.L.2    Irish, W.3    Woo, J.4    Carroll, P.B.5    Abu-Elmagd, K.6
  • 190
    • 76449110495 scopus 로고    scopus 로고
    • Combination therapy in multiple sclerosis
    • 20170843 10.1016/S1474-4422(10)70007-7
    • Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299-308.
    • (2010) Lancet Neurol , vol.9 , Issue.3 , pp. 299-308
    • Conway, D.1    Cohen, J.A.2
  • 191
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    • 1:CAS:528:DC%2BD28XhsVens74%3D 10.1002/art.21519
    • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthr Rheum. 2006;54(1):26-37.
    • (2006) Arthr Rheum , vol.54 , Issue.1 , pp. 26-37
    • Breedveld, F.C.1    Weisman, M.H.2    Kavanaugh, A.F.3    Cohen, S.B.4    Pavelka, K.5    Van Vollenhoven, R.6
  • 192
    • 0037154138 scopus 로고    scopus 로고
    • An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS
    • 1:CAS:528:DC%2BD38XhtVyksLs%3D 11805267 10.1212/WNL.58.2.314
    • Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology. 2002;58(2):314-7.
    • (2002) Neurology , vol.58 , Issue.2 , pp. 314-317
    • Calabresi, P.A.1    Wilterdink, J.L.2    Rogg, J.M.3    Mills, P.4    Webb, A.5    Whartenby, K.A.6
  • 193
    • 15544375688 scopus 로고    scopus 로고
    • Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis
    • 1:CAS:528:DC%2BD2MXjtVymt7Y%3D 15794390 10.1191/1352458505ms1141oa
    • Pulicken M, Bash CN, Costello K, Said A, Cuffari C, Wilterdink JL, et al. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler. 2005;11(2):169-74.
    • (2005) Mult Scler , vol.11 , Issue.2 , pp. 169-174
    • Pulicken, M.1    Bash, C.N.2    Costello, K.3    Said, A.4    Cuffari, C.5    Wilterdink, J.L.6
  • 194
    • 62149143732 scopus 로고    scopus 로고
    • Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
    • 1:STN:280:DC%2BD1M7ivF2lsA%3D%3D 19204263 10.1212/01.wnl.0000341934. 12142.74
    • Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6):535-41.
    • (2009) Neurology , vol.72 , Issue.6 , pp. 535-541
    • Cohen, J.A.1    Imrey, P.B.2    Calabresi, P.A.3    Edwards, K.R.4    Eickenhorst, T.5    Felton III, W.L.6
  • 195
    • 77953618723 scopus 로고    scopus 로고
    • Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): A multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
    • 1:CAS:528:DC%2BC3cXpsFajtbc%3D 20542736 10.1016/S1474-4422(10)70132-0
    • Ravnborg M, Sorensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672-80.
    • (2010) Lancet Neurol , vol.9 , Issue.7 , pp. 672-680
    • Ravnborg, M.1    Sorensen, P.S.2    Andersson, M.3    Celius, E.G.4    Jongen, P.J.5    Elovaara, I.6
  • 196
    • 65549144672 scopus 로고    scopus 로고
    • NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): A randomised, placebo-controlled trial
    • 1:CAS:528:DC%2BD1MXmvVyjur8%3D 19409854 10.1016/S1474-4422(09)70085-7
    • Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009;8(6):519-29.
    • (2009) Lancet Neurol , vol.8 , Issue.6 , pp. 519-529
    • Sorensen, P.S.1    Mellgren, S.I.2    Svenningsson, A.3    Elovaara, I.4    Frederiksen, J.L.5    Beiske, A.G.6
  • 197
    • 62849118791 scopus 로고    scopus 로고
    • GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
    • 1:CAS:528:DC%2BD1MXit1Cgurw%3D 19255407 10.1212/01.wnl.0000343880.13764. 69
    • Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806-12.
    • (2009) Neurology , vol.72 , Issue.9 , pp. 806-812
    • Goodman, A.D.1    Rossman, H.2    Bar-Or, A.3    Miller, A.4    Miller, D.H.5    Schmierer, K.6
  • 198
    • 0034880661 scopus 로고    scopus 로고
    • Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis
    • 1:STN:280:DC%2BD3Mvms12nsA%3D%3D 11511721 10.1136/jnnp.71.3.404
    • Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71(3):404-7.
    • (2001) J Neurol Neurosurg Psychiatry , vol.71 , Issue.3 , pp. 404-407
    • Patti, F.1    Cataldi, M.L.2    Nicoletti, F.3    Reggio, E.4    Nicoletti, A.5    Reggio, A.6
  • 199
    • 26644463420 scopus 로고    scopus 로고
    • The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients: Twenty-four months follow-up
    • 1:CAS:528:DC%2BD2MXht1CgsL3F 15940386 10.1007/s00415-005-0857-1
    • Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients: twenty-four months follow-up. J Neurol. 2005;252(10):1255-61.
    • (2005) J Neurol , vol.252 , Issue.10 , pp. 1255-1261
    • Reggio, E.1    Nicoletti, A.2    Fiorilla, T.3    Politi, G.4    Reggio, A.5    Patti, F.6
  • 200
    • 37749016994 scopus 로고    scopus 로고
    • Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: Treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
    • 17846110 10.1136/jnnp.2007.124958
    • Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79(1):52-6.
    • (2008) J Neurol Neurosurg Psychiatry , vol.79 , Issue.1 , pp. 52-56
    • Le Page, E.1    Leray, E.2    Taurin, G.3    Coustans, M.4    Chaperon, J.5    Morrissey, S.P.6
  • 201
    • 80855131644 scopus 로고    scopus 로고
    • Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: A 3-year randomised trial
    • 1:STN:280:DC%2BC38%2Fls12guw%3D%3D 21436229 10.1136/jnnp.2010.229724
    • Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82(12):1344-50.
    • (2011) J Neurol Neurosurg Psychiatry , vol.82 , Issue.12 , pp. 1344-1350
    • Edan, G.1    Comi, G.2    Le Page, E.3    Leray, E.4    Rocca, M.A.5    Filippi, M.6
  • 202
    • 79551714521 scopus 로고    scopus 로고
    • Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
    • 1:CAS:528:DC%2BC3MXjvFSitr0%3D 21448376
    • Etemadifar M, Kazemi M, Chitsaz A, Hekmatnia A, Tayari N, Ghazavi A, et al. Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study. J Res Med Sci. 2011;16(1):1-5.
    • (2011) J Res Med Sci , vol.16 , Issue.1 , pp. 1-5
    • Etemadifar, M.1    Kazemi, M.2    Chitsaz, A.3    Hekmatnia, A.4    Tayari, N.5    Ghazavi, A.6
  • 203
    • 77953404087 scopus 로고    scopus 로고
    • A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
    • 1:CAS:528:DC%2BC3MXisVChurk%3D 21180633 10.1177/1756285609353354
    • Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, et al. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2010;3(1):15-28.
    • (2010) Ther Adv Neurol Disord , vol.3 , Issue.1 , pp. 15-28
    • Frohman, E.M.1    Cutter, G.2    Remington, G.3    Gao, H.4    Rossman, H.5    Weinstock-Guttman, B.6
  • 204
    • 79960341237 scopus 로고    scopus 로고
    • Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial
    • 1:CAS:528:DC%2BC3MXptlyqsLk%3D 21742556 10.1016/S1474-4422(11)70144-2
    • Sorensen PS, Lycke J, Eralinna JP, Edland A, Wu X, Frederiksen JL, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691-701.
    • (2011) Lancet Neurol , vol.10 , Issue.8 , pp. 691-701
    • Sorensen, P.S.1    Lycke, J.2    Eralinna, J.P.3    Edland, A.4    Wu, X.5    Frederiksen, J.L.6
  • 205
    • 0017094715 scopus 로고
    • A trial of antilymphocyte globulin in the treatment of chronic progressive multiple sclerosis
    • 1:STN:280:DyaE2s%2FjtVKmsQ%3D%3D 978212 10.1016/0022-510X(76)90179-9
    • Walker JE, Hoehn MM, Kashiwagi N. A trial of antilymphocyte globulin in the treatment of chronic progressive multiple sclerosis. J Neurol Sci. 1976;29(2-4):303-9.
    • (1976) J Neurol Sci , vol.29 , Issue.2-4 , pp. 303-309
    • Walker, J.E.1    Hoehn, M.M.2    Kashiwagi, N.3
  • 206
    • 33644608613 scopus 로고    scopus 로고
    • Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    • 1:CAS:528:DC%2BD28XitVertLw%3D 16510745 10.1056/NEJMoa044396
    • Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-23.
    • (2006) N Engl J Med , vol.354 , Issue.9 , pp. 911-923
    • Rudick, R.A.1    Stuart, W.H.2    Calabresi, P.A.3    Confavreux, C.4    Galetta, S.L.5    Radue, E.W.6
  • 207
    • 84856724312 scopus 로고    scopus 로고
    • Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
    • 22312009 10.1177/1352458511435105 1:CAS:528:DC%2BC38XltFKjs7c%3D
    • Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143-52.
    • (2012) Mult Scler , vol.18 , Issue.2 , pp. 143-152
    • Sorensen, P.S.1    Bertolotto, A.2    Edan, G.3    Giovannoni, G.4    Gold, R.5    Havrdova, E.6
  • 208
    • 84856252354 scopus 로고    scopus 로고
    • Immune mechanisms of new therapeutic strategies in multiple sclerosis - A focus on alemtuzumab
    • 1:CAS:528:DC%2BC38XhsF2is7k%3D 21550857 10.1016/j.clim.2011.04.006
    • Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis - a focus on alemtuzumab. Clin Immunol. 2012;142(1):25-30.
    • (2012) Clin Immunol , vol.142 , Issue.1 , pp. 25-30
    • Klotz, L.1    Meuth, S.G.2    Wiendl, H.3
  • 209
    • 54949143968 scopus 로고    scopus 로고
    • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
    • 18946064 10.1056/NEJMoa0802670
    • Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801.
    • (2008) N Engl J Med , vol.359 , Issue.17 , pp. 1786-1801
    • Coles, A.J.1    Compston, D.A.2    Selmaj, K.W.3    Lake, S.L.4    Moran, S.5    Margolin, D.H.6
  • 210
    • 84856057894 scopus 로고    scopus 로고
    • A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis
    • 1:STN:280:DC%2BC387mtVGjsQ%3D%3D 21899662 10.1111/j.1468-1331.2011.03507. x
    • Fox EJ, Sullivan HC, Gazda SK, Mayer L, O'Donnell L, Melia K, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol. 2012;19(2):307-11.
    • (2012) Eur J Neurol , vol.19 , Issue.2 , pp. 307-311
    • Fox, E.J.1    Sullivan, H.C.2    Gazda, S.K.3    Mayer, L.4    O'Donnell, L.5    Melia, K.6
  • 211
    • 80053207130 scopus 로고    scopus 로고
    • Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
    • 1:CAS:528:DC%2BC3MXhtVSnsrzK 21795656 10.1212/WNL.0b013e318228bec5
    • Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-9.
    • (2011) Neurology , vol.77 , Issue.6 , pp. 573-579
    • Cossburn, M.1    Pace, A.A.2    Jones, J.3    Ali, R.4    Ingram, G.5    Baker, K.6
  • 212
    • 34249734136 scopus 로고    scopus 로고
    • New concepts on progressive multiple sclerosis
    • 17488590 10.1007/s11910-007-0036-0
    • Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep. 2007;7(3):239-44.
    • (2007) Curr Neurol Neurosci Rep , vol.7 , Issue.3 , pp. 239-244
    • Lassmann, H.1
  • 213
    • 33845395095 scopus 로고    scopus 로고
    • B-cells in multiple sclerosis
    • 1:STN:280:DC%2BD28nms1Kitw%3D%3D 17101076
    • Duddy M, Bar-Or A. B-cells in multiple sclerosis. Int MS J. 2006;13(3):84-90.
    • (2006) Int MS J , vol.13 , Issue.3 , pp. 84-90
    • Duddy, M.1    Bar-Or, A.2
  • 214
    • 0028057250 scopus 로고
    • Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
    • 1:CAS:528:DyaK2cXhtVCnu70%3D 7506951
    • Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-45.
    • (1994) Blood , vol.83 , Issue.2 , pp. 435-445
    • Reff, M.E.1    Carner, K.2    Chambers, K.S.3    Chinn, P.C.4    Leonard, J.E.5    Raab, R.6
  • 215
    • 33751085414 scopus 로고    scopus 로고
    • Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
    • 1:CAS:528:DC%2BD28Xht1SmsL3N 16904756 10.1016/j.jneuroim.2006.06.029
    • Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180(1-2):63-70.
    • (2006) J Neuroimmunol , vol.180 , Issue.1-2 , pp. 63-70
    • Cross, A.H.1    Stark, J.L.2    Lauber, J.3    Ramsbottom, M.J.4    Lyons, J.A.5
  • 216
    • 41849116363 scopus 로고    scopus 로고
    • Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase i trial
    • 1:CAS:528:DC%2BD1cXlt1Cktb4%3D 18383069 10.1002/ana.21363
    • Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395-400.
    • (2008) Ann Neurol , vol.63 , Issue.3 , pp. 395-400
    • Bar-Or, A.1    Calabresi, P.A.2    Arnold, D.3    Markowitz, C.4    Shafer, S.5    Kasper, L.H.6
  • 217
    • 77953335494 scopus 로고    scopus 로고
    • Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
    • 1:CAS:528:DC%2BC3cXntF2gtb4%3D 20530322 10.1212/WNL.0b013e3181e24373
    • Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010;74(23):1860-7.
    • (2010) Neurology , vol.74 , Issue.23 , pp. 1860-1867
    • Naismith, R.T.1    Piccio, L.2    Lyons, J.A.3    Lauber, J.4    Tutlam, N.T.5    Parks, B.J.6
  • 218
    • 39049142995 scopus 로고    scopus 로고
    • B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
    • 1:CAS:528:DC%2BD1cXhvVehtb0%3D 18272891 10.1056/NEJMoa0706383
    • Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-88.
    • (2008) N Engl J Med , vol.358 , Issue.7 , pp. 676-688
    • Hauser, S.L.1    Waubant, E.2    Arnold, D.L.3    Vollmer, T.4    Antel, J.5    Fox, R.J.6
  • 219
    • 70449418132 scopus 로고    scopus 로고
    • Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
    • 1:CAS:528:DC%2BD1MXhsVehtr3N 19847908 10.1002/ana.21867
    • Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-71.
    • (2009) Ann Neurol , vol.66 , Issue.4 , pp. 460-471
    • Hawker, K.1    O'Connor, P.2    Freedman, M.S.3    Calabresi, P.A.4    Antel, J.5    Simon, J.6
  • 220
    • 81555202418 scopus 로고    scopus 로고
    • Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial
    • 1:CAS:528:DC%2BC3MXhsVyrs7nL 22047971 10.1016/S0140-6736(11)61649-8
    • Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779-87.
    • (2011) Lancet , vol.378 , Issue.9805 , pp. 1779-1787
    • Kappos, L.1    Li, D.2    Calabresi, P.A.3    O'Connor, P.4    Bar-Or, A.5    Barkhof, F.6
  • 221
    • 77949301468 scopus 로고    scopus 로고
    • Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
    • 1:CAS:528:DC%2BC3cXltF2ktL4%3D 20163990 10.1016/S1474-4422(10)70033-8
    • Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9(4):381-90.
    • (2010) Lancet Neurol , vol.9 , Issue.4 , pp. 381-390
    • Wynn, D.1    Kaufman, M.2    Montalban, X.3    Vollmer, T.4    Simon, J.5    Elkins, J.6
  • 222
    • 82955225356 scopus 로고    scopus 로고
    • Intrathecal effects of daclizumab treatment of multiple sclerosis
    • 1:CAS:528:DC%2BC3MXhsFanu7vK 22076546 10.1212/WNL.0b013e318239f7ef
    • Bielekova B, Richert N, Herman ML, Ohayon J, Waldmann TA, McFarland H, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology. 2011;77(21):1877-86.
    • (2011) Neurology , vol.77 , Issue.21 , pp. 1877-1886
    • Bielekova, B.1    Richert, N.2    Herman, M.L.3    Ohayon, J.4    Waldmann, T.A.5    McFarland, H.6
  • 223
    • 0028812791 scopus 로고
    • Mechanisms of action and overview of OKT3
    • 1:CAS:528:DyaK28XltlGitw%3D%3D 8588230 10.1097/00007691-199512000-00012
    • Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit. 1995;17(6):615-20.
    • (1995) Ther Drug Monit , vol.17 , Issue.6 , pp. 615-620
    • Norman, D.J.1
  • 224
    • 0029973130 scopus 로고    scopus 로고
    • Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3
    • 1:STN:280:DyaK28zmslersQ%3D%3D
    • Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transpl. 1996;15(5):435-42.
    • (1996) J Heart Lung Transpl , vol.15 , Issue.5 , pp. 435-442
    • Bonnefoy-Berard, N.1    Revillard, J.P.2
  • 225
    • 0030745107 scopus 로고    scopus 로고
    • Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection
    • 1:CAS:528:DyaK2sXksl2msrs%3D 9232443 10.1016/S0165-2478(97)00092-8
    • Reinke P, Schwinzer H, Hoflich C, Ode-Hakim C, Docke WD, Frei U, et al. Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection. Immunol Lett. 1997;57(1-3):151-3.
    • (1997) Immunol Lett , vol.57 , Issue.1-3 , pp. 151-153
    • Reinke, P.1    Schwinzer, H.2    Hoflich, C.3    Ode-Hakim, C.4    Docke, W.D.5    Frei, U.6
  • 226
    • 0026018158 scopus 로고
    • An open trial of OKT3 in patients with multiple sclerosis
    • 1:STN:280:DyaK3M3ps1Witw%3D%3D 1906145 10.1212/WNL.41.7.1047
    • Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GP. An open trial of OKT3 in patients with multiple sclerosis. Neurology. 1991;41(7):1047-52.
    • (1991) Neurology , vol.41 , Issue.7 , pp. 1047-1052
    • Weinshenker, B.G.1    Bass, B.2    Karlik, S.3    Ebers, G.C.4    Rice, G.P.5
  • 227
    • 0026771135 scopus 로고
    • Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta)
    • 1:CAS:528:DyaK38Xls1yqtL8%3D 1329840 10.1016/0952-7915(92)90084-R
    • Ruddle NH. Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta). Curr Opin Immunol. 1992;4(3):327-32.
    • (1992) Curr Opin Immunol , vol.4 , Issue.3 , pp. 327-332
    • Ruddle, N.H.1
  • 228
    • 0029751983 scopus 로고    scopus 로고
    • Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
    • 8960740 10.1212/WNL.47.6.1531
    • van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47(6):1531-4.
    • (1996) Neurology , vol.47 , Issue.6 , pp. 1531-1534
    • Van Oosten, B.W.1    Barkhof, F.2    Truyen, L.3    Boringa, J.B.4    Bertelsmann, F.W.5    Von Blomberg, B.M.6
  • 229
    • 79955646245 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: An ongoing story
    • 1:CAS:528:DC%2BC3MXmtFCmt7Y%3D 21474190 10.1016/j.jneuroim.2011.03.004
    • Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: an ongoing story. J Neuroimmunol. 2011;234(1-2):1-6.
    • (2011) J Neuroimmunol , vol.234 , Issue.1-2 , pp. 1-6
    • Caminero, A.1    Comabella, M.2    Montalban, X.3
  • 230
    • 77951073508 scopus 로고    scopus 로고
    • Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis
    • 1:CAS:528:DC%2BC3cXksFSgt7g%3D 20061941 10.1097/WNF.0b013e3181cbf825
    • Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91-101.
    • (2010) Clin Neuropharmacol , vol.33 , Issue.2 , pp. 91-101
    • Chun, J.1    Hartung, H.P.2
  • 231
    • 77955358808 scopus 로고    scopus 로고
    • Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
    • 1:CAS:528:DC%2BC3cXpslWqsL8%3D 20592255 10.1212/WNL.0b013e3181ebdd64
    • Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010;75(5):403-10.
    • (2010) Neurology , vol.75 , Issue.5 , pp. 403-410
    • Mehling, M.1    Lindberg, R.2    Raulf, F.3    Kuhle, J.4    Hess, C.5    Kappos, L.6
  • 232
    • 0037379202 scopus 로고    scopus 로고
    • Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment
    • 1:CAS:528:DC%2BD3sXis1antb4%3D 12649354 10.1124/jpet.102.045658
    • Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003;305(1):70-7.
    • (2003) J Pharmacol Exp Ther , vol.305 , Issue.1 , pp. 70-77
    • Fujino, M.1    Funeshima, N.2    Kitazawa, Y.3    Kimura, H.4    Amemiya, H.5    Suzuki, S.6
  • 233
    • 77955799815 scopus 로고    scopus 로고
    • Oral fingolimod (FTY720) for relapsing multiple sclerosis
    • 1:CAS:528:DC%2BD28XpsFKku78%3D 16971719 10.1056/NEJMoa052643
    • Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-40.
    • (2006) N Engl J Med , vol.355 , Issue.11 , pp. 1124-1140
    • Kappos, L.1    Antel, J.2    Comi, G.3    Montalban, X.4    O'Connor, P.5    Polman, C.H.6
  • 234
    • 76149093586 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    • 1:CAS:528:DC%2BC3cXhvVWltr4%3D 20089952 10.1056/NEJMoa0909494
    • Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
    • (2010) N Engl J Med , vol.362 , Issue.5 , pp. 387-401
    • Kappos, L.1    Radue, E.W.2    O'Connor, P.3    Polman, C.4    Hohlfeld, R.5    Calabresi, P.6
  • 235
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • 1:CAS:528:DC%2BC3cXhvVWrsbk%3D 20089954 10.1056/NEJMoa0907839
    • Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15.
    • (2010) N Engl J Med , vol.362 , Issue.5 , pp. 402-415
    • Cohen, J.A.1    Barkhof, F.2    Comi, G.3    Hartung, H.P.4    Khatri, B.O.5    Montalban, X.6
  • 236
    • 79956024142 scopus 로고    scopus 로고
    • Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study
    • 1:CAS:528:DC%2BC3MXmsFanurg%3D 21571593 10.1016/S1474-4422(11)70099-0
    • Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10(6):520-9.
    • (2011) Lancet Neurol , vol.10 , Issue.6 , pp. 520-529
    • Khatri, B.1    Barkhof, F.2    Comi, G.3    Hartung, H.P.4    Kappos, L.5    Montalban, X.6
  • 237
    • 78650365286 scopus 로고    scopus 로고
    • Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis
    • 1:CAS:528:DC%2BC3cXhsVCjurfO 21157651
    • Palmer AM. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Investig Drugs. 2010;11(11):1313-23.
    • (2010) Curr Opin Investig Drugs , vol.11 , Issue.11 , pp. 1313-1323
    • Palmer, A.M.1
  • 238
    • 33645799680 scopus 로고    scopus 로고
    • A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    • 16567708 10.1212/01.wnl.0000203121.04509.31 1:CAS:528: DC%2BD28XitFOiurs%3D
    • O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900.
    • (2006) Neurology , vol.66 , Issue.6 , pp. 894-900
    • O'Connor, P.W.1    Li, D.2    Freedman, M.S.3    Bar-Or, A.4    Rice, G.P.5    Confavreux, C.6
  • 239
    • 84860199056 scopus 로고    scopus 로고
    • Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: Safety and efficacy results up to 8.5 years
    • 22307384 10.1177/1352458512436594
    • Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18(9):1278-89.
    • (2012) Mult Scler , vol.18 , Issue.9 , pp. 1278-1289
    • Confavreux, C.1    Li, D.K.2    Freedman, M.S.3    Truffinet, P.4    Benzerdjeb, H.5    Wang, D.6
  • 240
    • 80053533877 scopus 로고    scopus 로고
    • Randomized trial of oral teriflunomide for relapsing multiple sclerosis
    • 21991951 10.1056/NEJMoa1014656
    • O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303.
    • (2011) N Engl J Med , vol.365 , Issue.14 , pp. 1293-1303
    • O'Connor, P.1    Wolinsky, J.S.2    Confavreux, C.3    Comi, G.4    Kappos, L.5    Olsson, T.P.6
  • 242
    • 0030731322 scopus 로고    scopus 로고
    • Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells
    • 1:CAS:528:DyaK2sXnsVent7g%3D 9344704 10.1006/clin.1997.4444
    • Lehmann D, Karussis D, Mizrachi-Koll R, Linde AS, Abramsky O. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells. Clin Immunol Immunopathol. 1997;85(2):202-9.
    • (1997) Clin Immunol Immunopathol , vol.85 , Issue.2 , pp. 202-209
    • Lehmann, D.1    Karussis, D.2    Mizrachi-Koll, R.3    Linde, A.S.4    Abramsky, O.5
  • 243
    • 0034003613 scopus 로고    scopus 로고
    • Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials
    • 10773855
    • Tan IL, Lycklama à Nijeholt GJ, Polman CH, Adèr HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler. 2000;6(2):99-104.
    • (2000) Mult Scler , vol.6 , Issue.2 , pp. 99-104
    • Tan, I.L.1    Lycklama Nijeholt, À.G.J.2    Polman, C.H.3    Adèr, H.J.4    Barkhof, F.5
  • 244
    • 84856214549 scopus 로고    scopus 로고
    • Laquinimod in multiple sclerosis
    • 1:CAS:528:DC%2BC38XhsF2is7s%3D 21450529 10.1016/j.clim.2011.02.021
    • Giacomini PS, Bar-Or A. Laquinimod in multiple sclerosis. Clin Immunol. 2012;142(1):38-43.
    • (2012) Clin Immunol , vol.142 , Issue.1 , pp. 38-43
    • Giacomini, P.S.1    Bar-Or, A.2
  • 245
    • 45249107267 scopus 로고    scopus 로고
    • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
    • 1:STN:280:DC%2BD1cvgsVegtQ%3D%3D 18572078 10.1016/S0140-6736(08)60918-6
    • Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371(9630):2085-92.
    • (2008) Lancet , vol.371 , Issue.9630 , pp. 2085-2092
    • Comi, G.1    Pulizzi, A.2    Rovaris, M.3    Abramsky, O.4    Arbizu, T.5    Boiko, A.6
  • 246
    • 78449302875 scopus 로고    scopus 로고
    • Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
    • 1:STN:280:DC%2BC3cblvVygtQ%3D%3D 20834039 10.1177/1352458510378127
    • Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdova E, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010;16(11):1360-6.
    • (2010) Mult Scler , vol.16 , Issue.11 , pp. 1360-1366
    • Comi, G.1    Abramsky, O.2    Arbizu, T.3    Boyko, A.4    Gold, R.5    Havrdova, E.6
  • 247
    • 84858217865 scopus 로고    scopus 로고
    • Placebo-controlled trial of oral laquinimod for multiple sclerosis
    • 1:CAS:528:DC%2BC38Xkt1yju7w%3D 22417253 10.1056/NEJMoa1104318
    • Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-9.
    • (2012) N Engl J Med , vol.366 , Issue.11 , pp. 1000-1009
    • Comi, G.1    Jeffery, D.2    Kappos, L.3    Montalban, X.4    Boyko, A.5    Rocca, M.A.6
  • 248
    • 79952136166 scopus 로고    scopus 로고
    • Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
    • 21354971 10.1093/brain/awq386
    • Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3):678-92.
    • (2011) Brain , vol.134 , Issue.PART 3 , pp. 678-692
    • Linker, R.A.1    Lee, D.H.2    Ryan, S.3    Van Dam, A.M.4    Conrad, R.5    Bista, P.6
  • 249
    • 78649502834 scopus 로고    scopus 로고
    • Dimethyl fumarate for multiple sclerosis
    • 1:CAS:528:DC%2BC3cXhsVOgu73M 21067468 10.1517/13543784.2010.534778
    • Papadopoulou A, D'Souza M, Kappos L, Yaldizli O. Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs. 2010;19(12):1603-12.
    • (2010) Expert Opin Investig Drugs , vol.19 , Issue.12 , pp. 1603-1612
    • Papadopoulou, A.1    D'Souza, M.2    Kappos, L.3    Yaldizli, O.4
  • 250
    • 33745051595 scopus 로고    scopus 로고
    • Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study
    • 1:STN:280:DC%2BD28zotFagsw%3D%3D 16796584 10.1111/j.1468-1331.2006.01292. x
    • Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13(6):604-10.
    • (2006) Eur J Neurol , vol.13 , Issue.6 , pp. 604-610
    • Schimrigk, S.1    Brune, N.2    Hellwig, K.3    Lukas, C.4    Bellenberg, B.5    Rieks, M.6
  • 251
    • 54149116366 scopus 로고    scopus 로고
    • Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
    • 1:CAS:528:DC%2BD1cXht12gtLrE 18970976 10.1016/S0140-6736(08)61619-0
    • Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-72.
    • (2008) Lancet , vol.372 , Issue.9648 , pp. 1463-1472
    • Kappos, L.1    Gold, R.2    Miller, D.H.3    Macmanus, D.G.4    Havrdova, E.5    Limmroth, V.6
  • 252
    • 84863284276 scopus 로고    scopus 로고
    • Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2b study
    • 1:CAS:528:DC%2BC38Xmt1Cit7c%3D 21878455 10.1177/1352458511421054
    • Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler. 2012;18(3):314-21.
    • (2012) Mult Scler , vol.18 , Issue.3 , pp. 314-321
    • Kappos, L.1    Gold, R.2    Miller, D.H.3    Macmanus, D.G.4    Havrdova, E.5    Limmroth, V.6
  • 253
    • 0019487117 scopus 로고
    • Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein
    • 1:STN:280:DyaL38%2FhtlGqtg%3D%3D 6974307 10.1038/292060a0
    • Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature. 1981;292(5818):60-1.
    • (1981) Nature , vol.292 , Issue.5818 , pp. 60-61
    • Ben-Nun, A.1    Wekerle, H.2    Cohen, I.R.3
  • 254
    • 0027448708 scopus 로고
    • MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination
    • 1:CAS:528:DyaK3sXmtVWgtLo%3D 7690157 10.1126/science.7690157
    • Zhang J, Medaer R, Stinissen P, Hafler D, Raus J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science. 1993;261(5127):1451-4.
    • (1993) Science , vol.261 , Issue.5127 , pp. 1451-1454
    • Zhang, J.1    Medaer, R.2    Stinissen, P.3    Hafler, D.4    Raus, J.5
  • 255
    • 0034710361 scopus 로고    scopus 로고
    • T cell vaccination in secondary progressive multiple sclerosis
    • 1:CAS:528:DC%2BD3cXjvFKgtb8%3D 10854647 10.1016/S0165-5728(00)00235-6
    • Correale J, Lund B, McMillan M, Ko DY, McCarthy K, Weiner LP. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol. 2000;107(2):130-9.
    • (2000) J Neuroimmunol , vol.107 , Issue.2 , pp. 130-139
    • Correale, J.1    Lund, B.2    McMillan, M.3    Ko, D.Y.4    McCarthy, K.5    Weiner, L.P.6
  • 256
    • 0032881571 scopus 로고    scopus 로고
    • Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination
    • 1:STN:280:DyaK1MvhtVamtA%3D%3D 10479392 10.1006/jaut.1999.0314
    • Hermans G, Denzer U, Lohse A, Raus J, Stinissen P. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmun. 1999;13(2):233-46.
    • (1999) J Autoimmun , vol.13 , Issue.2 , pp. 233-246
    • Hermans, G.1    Denzer, U.2    Lohse, A.3    Raus, J.4    Stinissen, P.5
  • 257
    • 0033991945 scopus 로고    scopus 로고
    • Myelin reactive T cells after T cell vaccination in multiple sclerosis: Cytokine profile and depletion by additional immunizations
    • 1:CAS:528:DyaK1MXotVKqtrc%3D 10626670 10.1016/S0165-5728(99)00157-5
    • Hermans G, Medaer R, Raus J, Stinissen P. Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol. 2000;102(1):79-84.
    • (2000) J Neuroimmunol , vol.102 , Issue.1 , pp. 79-84
    • Hermans, G.1    Medaer, R.2    Raus, J.3    Stinissen, P.4
  • 258
    • 0029167057 scopus 로고
    • Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: Pilot trial in multiple sclerosis
    • 1:STN:280:DyaK2MvgsFSktw%3D%3D 7545769 10.1016/S0140-6736(95)91622-9
    • Medaer R, Stinissen P, Truyen L, Raus J, Zhang J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet. 1995;346(8978):807-8.
    • (1995) Lancet , vol.346 , Issue.8978 , pp. 807-808
    • Medaer, R.1    Stinissen, P.2    Truyen, L.3    Raus, J.4    Zhang, J.5
  • 259
    • 0029782340 scopus 로고    scopus 로고
    • Vaccination with autoreactive T cell clones in multiple sclerosis: Overview of immunological and clinical data
    • 1:CAS:528:DyaK28XlsVOksb4%3D 8872912 10.1002/(SICI)1097-4547(19960815)45: 4<500: AID-JNR21>3.0.CO;2-2
    • Stinissen P, Zhang J, Medaer R, Vandevyver C, Raus J. Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. J Neurosci Res. 1996;45(4):500-11.
    • (1996) J Neurosci Res , vol.45 , Issue.4 , pp. 500-511
    • Stinissen, P.1    Zhang, J.2    Medaer, R.3    Vandevyver, C.4    Raus, J.5
  • 260
    • 0036169323 scopus 로고    scopus 로고
    • T cell vaccination in multiple sclerosis: Results of a preliminary study
    • 11985389 10.1007/PL00007867
    • Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, et al. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol. 2002;249(2):212-8.
    • (2002) J Neurol , vol.249 , Issue.2 , pp. 212-218
    • Zhang, J.Z.1    Rivera, V.M.2    Tejada-Simon, M.V.3    Yang, D.4    Hong, J.5    Li, S.6
  • 261
    • 47049096574 scopus 로고    scopus 로고
    • Autologous T-cell vaccination for multiple sclerosis: A perspective on progress
    • 18611069 10.2165/00063030-200822040-00006
    • Vandenbark AA, Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs. 2008;22(4):265-73.
    • (2008) BioDrugs , vol.22 , Issue.4 , pp. 265-273
    • Vandenbark, A.A.1    Abulafia-Lapid, R.2
  • 262
    • 4644338002 scopus 로고    scopus 로고
    • T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients
    • 1:CAS:528:DC%2BD2cXnvVyrur4%3D 15451472 10.1016/j.clim.2004.06.004
    • Achiron A, Lavie G, Kishner I, Stern Y, Sarova-Pinhas I, Ben-Aharon T, et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol. 2004;113(2):155-60.
    • (2004) Clin Immunol , vol.113 , Issue.2 , pp. 155-160
    • Achiron, A.1    Lavie, G.2    Kishner, I.3    Stern, Y.4    Sarova-Pinhas, I.5    Ben-Aharon, T.6
  • 263
    • 25844508410 scopus 로고    scopus 로고
    • A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis
    • 1:CAS:528:DC%2BD2MXhtFGlsb7J 16193893 10.1191/1352458505ms1225oa
    • Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler. 2005;11(5):552-61.
    • (2005) Mult Scler , vol.11 , Issue.5 , pp. 552-561
    • Bourdette, D.N.1    Edmonds, E.2    Smith, C.3    Bowen, J.D.4    Guttmann, C.R.5    Nagy, Z.P.6
  • 264
    • 16044361810 scopus 로고    scopus 로고
    • Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial
    • 1:STN:280:DyaK28vjsVKrtw%3D%3D 8837609 10.1038/nm1096-1109
    • Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeld D, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med. 1996;2(10):1109-15.
    • (1996) Nat Med , vol.2 , Issue.10 , pp. 1109-1115
    • Vandenbark, A.A.1    Chou, Y.K.2    Whitham, R.3    Mass, M.4    Buenafe, A.5    Liefeld, D.6
  • 265
    • 28744442319 scopus 로고    scopus 로고
    • Antigen-specific therapies in multiple sclerosis: Going beyond proteins and peptides
    • 1:CAS:528:DC%2BD2MXht1GltLzN 16318989 10.1080/08830180500379655
    • Fontoura P, Garren H, Steinman L. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int Rev Immunol. 2005;24(5-6):415-46.
    • (2005) Int Rev Immunol , vol.24 , Issue.5-6 , pp. 415-446
    • Fontoura, P.1    Garren, H.2    Steinman, L.3
  • 266
    • 0033791462 scopus 로고    scopus 로고
    • Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group
    • 1:CAS:528:DC%2BD3cXntlKmsLw%3D 11017151 10.1038/80525
    • Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med. 2000;6(10):1176-82.
    • (2000) Nat Med , vol.6 , Issue.10 , pp. 1176-1182
    • Kappos, L.1    Comi, G.2    Panitch, H.3    Oger, J.4    Antel, J.5    Conlon, P.6
  • 267
    • 0033786776 scopus 로고    scopus 로고
    • Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
    • 1:CAS:528:DC%2BD3cXntlKmsr4%3D 11017150 10.1038/80516
    • Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6(10):1167-75.
    • (2000) Nat Med , vol.6 , Issue.10 , pp. 1167-1175
    • Bielekova, B.1    Goodwin, B.2    Richert, N.3    Cortese, I.4    Kondo, T.5    Afshar, G.6
  • 268
    • 0026046280 scopus 로고
    • Antigen-driven bystander suppression after oral administration of antigens
    • 1:CAS:528:DyaK3MXmtVGntb4%3D 1717632 10.1084/jem.174.4.791
    • Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med. 1991;174(4):791-8.
    • (1991) J Exp Med , vol.174 , Issue.4 , pp. 791-798
    • Miller, A.1    Lider, O.2    Weiner, H.L.3
  • 269
    • 14544294320 scopus 로고    scopus 로고
    • Current issues in the treatment of human diseases by mucosal tolerance
    • 1:CAS:528:DC%2BD2MXislWisbo%3D 15681760 10.1196/annals.1309.053
    • Weiner HL. Current issues in the treatment of human diseases by mucosal tolerance. Ann N Y Acad Sci. 2004;1029:211-24.
    • (2004) Ann N y Acad Sci , vol.1029 , pp. 211-224
    • Weiner, H.L.1
  • 270
    • 0027467440 scopus 로고
    • Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
    • 1:STN:280:DyaK3s7ptVWjtg%3D%3D 7680493 10.1126/science.7680493
    • Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993;259(5099):1321-4.
    • (1993) Science , vol.259 , Issue.5099 , pp. 1321-1324
    • Weiner, H.L.1    Mackin, G.A.2    Matsui, M.3    Orav, E.J.4    Khoury, S.J.5    Dawson, D.M.6
  • 271
    • 0029867975 scopus 로고    scopus 로고
    • Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial
    • 1:STN:280:DyaK287nslCjtA%3D%3D 8610977 10.1111/j.1749-6632.1996.tb21132.x
    • Hohol MJ, Khoury SJ, Cook SL, Orav EJ, Hafler DA, Weiner HL. Three-year open protocol continuation study of oral tolerization with myelin antigens in
    • (1996) Ann N y Acad Sci , vol.778 , pp. 243-250
    • Hohol, M.J.1    Khoury, S.J.2    Cook, S.L.3    Orav, E.J.4    Hafler, D.A.5    Weiner, H.L.6
  • 272
    • 0028879188 scopus 로고
    • Administration of myelin basic protein synthetic peptides to multiple sclerosis patients
    • 1:CAS:528:DyaK28XjvF2isQ%3D%3D 8583237 10.1016/0022-510X(95)00187-7
    • Warren KG, Catz I. Administration of myelin basic protein synthetic peptides to multiple sclerosis patients. J Neurol Sci. 1995;133(1-2):85-94.
    • (1995) J Neurol Sci , vol.133 , Issue.1-2 , pp. 85-94
    • Warren, K.G.1    Catz, I.2
  • 273
    • 0030856261 scopus 로고    scopus 로고
    • Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis
    • 1:CAS:528:DyaK2sXmsl2ms78%3D 9395124 10.1016/S0022-510X(97)00130-5
    • Warren KG, Catz I, Wucherpfennig KW. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci. 1997;152(1):31-8.
    • (1997) J Neurol Sci , vol.152 , Issue.1 , pp. 31-38
    • Warren, K.G.1    Catz, I.2    Wucherpfennig, K.W.3
  • 274
    • 0033754799 scopus 로고    scopus 로고
    • Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP(85)VVHFFKNIVTP(96)RT in multiple sclerosis patients
    • 1:CAS:528:DC%2BD3cXot1aisrc%3D 11064438
    • Warren KG, Catz I. Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP(85)VVHFFKNIVTP(96)RT in multiple sclerosis patients. Mult Scler. 2000;6(5):300-11.
    • (2000) Mult Scler , vol.6 , Issue.5 , pp. 300-311
    • Warren, K.G.1    Catz, I.2
  • 275
    • 0034636191 scopus 로고    scopus 로고
    • A phase i trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis
    • 1:CAS:528:DC%2BD3cXivFOitLc%3D 10751249 10.1212/WNL.54.7.1414
    • Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, et al. A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. Neurology. 2000;54(7):1414-20.
    • (2000) Neurology , vol.54 , Issue.7 , pp. 1414-1420
    • Goodkin, D.E.1    Shulman, M.2    Winkelhake, J.3    Waubant, E.4    Andersson, P.5    Stewart, T.6
  • 276
    • 0027329005 scopus 로고
    • Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation
    • 1:STN:280:DyaK3szlt1yhsA%3D%3D 7688762 10.1172/JCI116648
    • Karussis DM, Vourka-Karussis U, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest. 1993;92(2):765-72.
    • (1993) J Clin Invest , vol.92 , Issue.2 , pp. 765-772
    • Karussis, D.M.1    Vourka-Karussis, U.2    Lehmann, D.3    Ovadia, H.4    Mizrachi-Koll, R.5    Ben-Nun, A.6
  • 277
    • 0026604243 scopus 로고
    • Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation
    • 1:STN:280:DyaK387ns1Khtg%3D%3D 1541813
    • Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol. 1992;148(6):1693-8.
    • (1992) J Immunol , vol.148 , Issue.6 , pp. 1693-1698
    • Karussis, D.M.1    Slavin, S.2    Lehmann, D.3    Mizrachi-Koll, R.4    Abramsky, O.5    Ben-Nun, A.6
  • 278
    • 0030714110 scopus 로고    scopus 로고
    • Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study
    • 1:STN:280:DyaK1c%2FktlGksQ%3D%3D 10.1038/sj.bmt.1700944
    • Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transpl. 1997;20(8):631-8.
    • (1997) Bone Marrow Transpl , vol.20 , Issue.8 , pp. 631-638
    • Fassas, A.1    Anagnostopoulos, A.2    Kazis, A.3    Kapinas, K.4    Sakellari, I.5    Kimiskidis, V.6
  • 279
    • 30644470006 scopus 로고    scopus 로고
    • Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis
    • 16388358 10.1007/s10072-005-0514-6
    • Capello E, Saccardi R, Murialdo A, Gualandi F, Pagliai F, Bacigalupo A, et al. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol Sci. 2005;26(Suppl. 4):S200-3.
    • (2005) Neurol Sci , vol.26 , Issue.SUPPL. 4
    • Capello, E.1    Saccardi, R.2    Murialdo, A.3    Gualandi, F.4    Pagliai, F.5    Bacigalupo, A.6
  • 280
    • 20144364694 scopus 로고    scopus 로고
    • Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis
    • 15957523 10.1191/1352458505ms1181cr
    • Mancardi GL, Murialdo A, Rossi P, Gualandi F, Martino G, Marmont A, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler. 2005;11(3):367-71.
    • (2005) Mult Scler , vol.11 , Issue.3 , pp. 367-371
    • Mancardi, G.L.1    Murialdo, A.2    Rossi, P.3    Gualandi, F.4    Martino, G.5    Marmont, A.6
  • 281
    • 60049083956 scopus 로고    scopus 로고
    • Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study
    • 1:CAS:528:DC%2BD1MXjvVWisLk%3D 19186105 10.1016/S1474-4422(09)70017-1
    • Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8(3):244-53.
    • (2009) Lancet Neurol , vol.8 , Issue.3 , pp. 244-253
    • Burt, R.K.1    Loh, Y.2    Cohen, B.3    Stefoski, D.4    Balabanov, R.5    Katsamakis, G.6
  • 282
    • 77952012521 scopus 로고    scopus 로고
    • Hematopoietic stem cell transplantation in multiple sclerosis: A review of the clinical experience and a report of an international meeting
    • 20441420 10.1586/eci.10.7
    • Karussis D, Vaknin-Dembinsky A. Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting. Expert Rev Clin Immunol. 2010;6(3):347-52.
    • (2010) Expert Rev Clin Immunol , vol.6 , Issue.3 , pp. 347-352
    • Karussis, D.1    Vaknin-Dembinsky, A.2
  • 283
    • 0346494281 scopus 로고    scopus 로고
    • Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis
    • 1:CAS:528:DC%2BD3sXpvFymt7Y%3D 14697670 10.1016/j.mcn.2003.08.009
    • Einstein O, Karussis D, Grigoriadis N, Mizrachi-Kol R, Reinhartz E, Abramsky O, et al. Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis. Mol Cell Neurosci. 2003;24(4):1074-82.
    • (2003) Mol Cell Neurosci , vol.24 , Issue.4 , pp. 1074-1082
    • Einstein, O.1    Karussis, D.2    Grigoriadis, N.3    Mizrachi-Kol, R.4    Reinhartz, E.5    Abramsky, O.6
  • 284
    • 0037254564 scopus 로고    scopus 로고
    • Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis
    • 12465047 10.1002/glia.10159
    • Ben-Hur T, Einstein O, Mizrachi-Kol R, Ben-Menachem O, Reinhartz E, Karussis D, et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. 2003;41(1):73-80.
    • (2003) Glia , vol.41 , Issue.1 , pp. 73-80
    • Ben-Hur, T.1    Einstein, O.2    Mizrachi-Kol, R.3    Ben-Menachem, O.4    Reinhartz, E.5    Karussis, D.6
  • 285
    • 84979726329 scopus 로고    scopus 로고
    • Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis
    • 1:CAS:528:DC%2BD3sXivFGhsLg%3D 12700753 10.1038/nature01552
    • Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 2003;422(6933):688-94.
    • (2003) Nature , vol.422 , Issue.6933 , pp. 688-694
    • Pluchino, S.1    Quattrini, A.2    Brambilla, E.3    Gritti, A.4    Salani, G.5    Dina, G.6
  • 286
    • 23944519424 scopus 로고    scopus 로고
    • Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy
    • 1:CAS:528:DC%2BD2MXps1Ogtrk%3D 15905186 10.1182/blood-2005-04-1496
    • Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755-61.
    • (2005) Blood , vol.106 , Issue.5 , pp. 1755-1761
    • Zappia, E.1    Casazza, S.2    Pedemonte, E.3    Benvenuto, F.4    Bonanni, I.5    Gerdoni, E.6
  • 287
    • 52149111208 scopus 로고    scopus 로고
    • Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis
    • 18773082 10.1371/journal.pone.0003145 1:CAS:528:DC%2BD1cXhtFKlsbrM
    • Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One. 2008;3(9):e3145.
    • (2008) PLoS One , vol.3 , Issue.9 , pp. 3145
    • Aharonowiz, M.1    Einstein, O.2    Fainstein, N.3    Lassmann, H.4    Reubinoff, B.5    Ben-Hur, T.6
  • 288
    • 45149103232 scopus 로고    scopus 로고
    • Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis
    • 18541795 10.1001/archneur.65.6.753
    • Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol. 2008;65(6):753-61.
    • (2008) Arch Neurol , vol.65 , Issue.6 , pp. 753-761
    • Kassis, I.1    Grigoriadis, N.2    Gowda-Kurkalli, B.3    Mizrachi-Kol, R.4    Ben-Hur, T.5    Slavin, S.6
  • 289
    • 36348977575 scopus 로고    scopus 로고
    • Immunomodulatory properties of mesenchymal stromal cells
    • 1:CAS:528:DC%2BD2sXhtlarurzE 17664353 10.1182/blood-2007-02-069716
    • Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-506.
    • (2007) Blood , vol.110 , Issue.10 , pp. 3499-3506
    • Nauta, A.J.1    Fibbe, W.E.2
  • 290
    • 34247645621 scopus 로고    scopus 로고
    • Mesenchymal stem cells: A new strategy for immunosuppression?
    • 1:CAS:528:DC%2BD2sXkslKqsr0%3D 17400510 10.1016/j.it.2007.03.001
    • Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007;28(5):219-26.
    • (2007) Trends Immunol , vol.28 , Issue.5 , pp. 219-226
    • Uccelli, A.1    Pistoia, V.2    Moretta, L.3
  • 291
    • 33750233770 scopus 로고    scopus 로고
    • Immunoregulatory function of mesenchymal stem cells
    • 1:CAS:528:DC%2BD28XhtFGqtrbI 17013987 10.1002/eji.200636416
    • Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006;36(10):2566-73.
    • (2006) Eur J Immunol , vol.36 , Issue.10 , pp. 2566-2573
    • Uccelli, A.1    Moretta, L.2    Pistoia, V.3
  • 292
    • 77956651196 scopus 로고    scopus 로고
    • Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study
    • 1:CAS:528:DC%2BC3cXhtFyisb%2FJ 20728948 10.1016/j.jneuroim.2010.07.013
    • Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010;227(1-2):185-9.
    • (2010) J Neuroimmunol , vol.227 , Issue.1-2 , pp. 185-189
    • Yamout, B.1    Hourani, R.2    Salti, H.3    Barada, W.4    El-Hajj, T.5    Al-Kutoubi, A.6
  • 293
    • 84856023693 scopus 로고    scopus 로고
    • Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study
    • 22236384 10.1016/S1474-4422(11)70305-2
    • Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150-6.
    • (2012) Lancet Neurol , vol.11 , Issue.2 , pp. 150-156
    • Connick, P.1    Kolappan, M.2    Crawley, C.3    Webber, D.J.4    Patani, R.5    Michell, A.W.6
  • 294
    • 17444424938 scopus 로고    scopus 로고
    • Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis
    • 15847841 10.1016/S1474-4422(05)70071-5
    • Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4(5):281-8.
    • (2005) Lancet Neurol , vol.4 , Issue.5 , pp. 281-288
    • Miller, D.1    Barkhof, F.2    Montalban, X.3    Thompson, A.4    Filippi, M.5
  • 295
    • 67649210709 scopus 로고    scopus 로고
    • MRI: The perfect surrogate marker for multiple sclerosis?
    • 19347020 10.1038/nrneurol.2009.31
    • Barkhof F, Filippi M. MRI: the perfect surrogate marker for multiple sclerosis? Nat Rev Neurol. 2009;5(4):182-3.
    • (2009) Nat Rev Neurol , vol.5 , Issue.4 , pp. 182-183
    • Barkhof, F.1    Filippi, M.2
  • 296
    • 0030832846 scopus 로고    scopus 로고
    • Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
    • 9397021 10.1093/brain/120.11.2059
    • Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11):2059-69.
    • (1997) Brain , vol.120 , Issue.PART 11 , pp. 2059-2069
    • Barkhof, F.1    Filippi, M.2    Miller, D.H.3    Scheltens, P.4    Campi, A.5    Polman, C.H.6
  • 297
    • 84863215864 scopus 로고    scopus 로고
    • Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: A BENEFIT study analysis
    • 1:STN:280:DC%2BC38zptFWruw%3D%3D 22183938 10.1177/1352458511432327
    • Freedman M, Metzig C, Kappos L, Polman C, Edan G, Hartung HP, et al. Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler. 2012;18(7):966-73.
    • (2012) Mult Scler , vol.18 , Issue.7 , pp. 966-973
    • Freedman, M.1    Metzig, C.2    Kappos, L.3    Polman, C.4    Edan, G.5    Hartung, H.P.6
  • 298
    • 33646093241 scopus 로고    scopus 로고
    • Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis
    • 1:CAS:528:DC%2BD28XjvVGmtbo%3D 16480743 10.1016/j.jns.2005.12.006
    • Schwarz M, Spector L, Gortler M, Weisshaus O, Glass-Marmor L, Karni A, et al. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci. 2006;244(1-2):59-68.
    • (2006) J Neurol Sci , vol.244 , Issue.1-2 , pp. 59-68
    • Schwarz, M.1    Spector, L.2    Gortler, M.3    Weisshaus, O.4    Glass-Marmor, L.5    Karni, A.6
  • 299
    • 0028348545 scopus 로고
    • Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis
    • 1:STN:280:DyaK2c7mvVChuw%3D%3D 7510098 10.1002/ana.410350307
    • Warren KG, Catz I, Johnson E, Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol. 1994;35(3):280-9.
    • (1994) Ann Neurol. , vol.35 , Issue.3 , pp. 280-289
    • Warren, K.G.1    Catz, I.2    Johnson, E.3    Mielke, B.4
  • 300
    • 0038790058 scopus 로고    scopus 로고
    • Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event
    • 1:CAS:528:DC%2BD3sXltlOrs7o%3D 12853586 10.1056/NEJMoa022328
    • Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349(2):139-45.
    • (2003) N Engl J Med , vol.349 , Issue.2 , pp. 139-145
    • Berger, T.1    Rubner, P.2    Schautzer, F.3    Egg, R.4    Ulmer, H.5    Mayringer, I.6
  • 301
    • 33645238738 scopus 로고    scopus 로고
    • A recommended treatment algorithm in relapsing multiple sclerosis: Report of an international consensus meeting
    • 1:STN:280:DC%2BD28%2FjtlSjtA%3D%3D 16420394 10.1111/j.1468-1331.2006. 01147.x
    • Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol. 2006;13(1):61-71.
    • (2006) Eur J Neurol , vol.13 , Issue.1 , pp. 61-71
    • Karussis, D.1    Biermann, L.D.2    Bohlega, S.3    Boiko, A.4    Chofflon, M.5    Fazekas, F.6
  • 302
    • 0842330009 scopus 로고    scopus 로고
    • Report of an international consensus meeting
    • Treatment optimization in multiple sclerosis 10.1046/j.1351-5101.2003. 00711.x
    • Treatment optimization in multiple sclerosis. Report of an international consensus meeting. Eur J Neurol. 2004;11(1):43-7.
    • (2004) Eur J Neurol , vol.11 , Issue.1 , pp. 43-47
  • 303
    • 0032879010 scopus 로고    scopus 로고
    • Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis
    • 1:CAS:528:DyaK1MXmtlGqsb4%3D 10496187 10.1016/S0165-5728(99)00039-9
    • Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol. 1999;99(1):142-9.
    • (1999) J Neuroimmunol , vol.99 , Issue.1 , pp. 142-149
    • Gobbini, M.I.1    Smith, M.E.2    Richert, N.D.3    Frank, J.A.4    McFarland, H.F.5
  • 304
    • 84871265763 scopus 로고    scopus 로고
    • T cell vaccination benefits relapsing progressive multiple sclerosis patients: A randomized, double-blind clinical trial
    • doi: 10.1371/journal.pone.0050478
    • Karussis D, Shor H, Yachnin J, Lanxner N, Amiel M, Baruch K, et al. T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial. PLoS One. 2012;7(12):e50478. doi: 10.1371/journal.pone.0050478
    • (2012) PLoS One , vol.7 , Issue.12
    • Karussis, D.1    Shor, H.2    Yachnin, J.3    Lanxner, N.4    Amiel, M.5    Baruch, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.